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ABSTRACT
GLYCEMIC VARIABILITY IN PATIENTS WITH STAGE II-III COLON CANCER
Natalie C. Mandolfo, PhD, MSN, APRN-NP
University of Nebraska, 2020
Advisor: Ann M. Berger, PhD, APRN, AOCNS, FAAN
Patients with cancer experience metabolic changes such as hypoglycemia, hyperglycemia, and
glycemic variability; collectively termed malglycemia. Glycemic variability, defined as
fluctuations in glucose, is a marker of metabolic instability. Higher glycemic variability is
associated with adverse health outcomes in the general population and in those with diabetes.
Little is known about glycemic variability in patients with cancer, especially those with solid
tumor malignancies. Glycemic variability is associated with increased infection, shorter periods
of remission, and higher mortality in patients with hematological cancer. This body of work
describes the concept and measurement of glycemic variability to assess glycemic control in
patients with cancer, provides a review of glycemic variability in patients with gastrointestinal
cancer, and presents results from research of glycemic variability in patients with stage II-III
colon cancer. The purpose of this retrospective, longitudinal study was to examine glycemic
variability within one year following surgery among patients treated with or without
chemotherapy for stage II-III colon cancer. Glycemic variability was measured as standard
deviation (SD) and % coefficient of variation (CV). Serial glucose values were used to assess
glycemic variability within one month following surgery, throughout chemotherapy, and within
one year following surgery. Patients with diabetes had significantly higher glycemic variability
within one month following surgery, throughout chemotherapy, and within one year following
surgery compared to patients without diabetes. Patients without diabetes experienced a
significant rise in glycemic variability throughout 12 cycles of chemotherapy; a finding not
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observed in patients with diabetes. Numerous associations between demographic and clinical
characteristics and glycemic variability were observed; these associations varied by preoperative
diabetes status, method of measurement (SD or CV), and timing of assessment. Preoperative
diabetes or higher preoperative glucose values was associated with higher glycemic variability
within one month and at year following surgery. The pre-chemotherapy glucose value was not
associated with glycemic variability throughout adjuvant chemotherapy. Results suggest that all
patients with stage II-III colon cancer, especially those with diabetes, are at-risk for higher
glycemic variability following surgery and throughout adjuvant chemotherapy. This dissertation
provides a foundation for future research focused on improving glycemic variability in at-risk
patients receiving cancer treatments.
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CHAPTER 1: INTRODUCTION
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CHAPTER 1: INTRODUCTION
Background and Significance
The rate of Type 2 Diabetes (T2D) in the United States (U.S.) is expected to rise from
35.6 million in 2015 to 54.9 million by 2030. This astonishing prediction does not include the
projected 40% of Americans that will develop prediabetes by 2030 (Rowley et al., 2017). The
incidence rate of T2D in the general population is 10.5% and patients with diabetes are known
to have a 27% higher risk of developing colon cancer compared to those without diabetes
(Centers for Disease Control and Prevention, 2020; Gonzalez et al., 2017). A hallmark
characteristic of T2D is hyperglycemia. Patients with cancer, regardless of underlying T2D status,
can experience hyperglycemia which increases the risks of adverse events (Hammer et al., 2009;
Hammer et al., 2019; Kuhlman et al., 2019). Fluctuations in glucose, known as glycemic
variability, has been associated with twice the risk of infections and as high as a 14.5 fold
increase in risk of non-relapse mortality in patients with hematologic cancers (Hammer et al.,
2009). Malglycemia is the triad of hypoglycemia, hyperglycemia, and glycemic variability
(Hammer et al., 2009). There are distinct differences between the three components of
malglycemia and each is an important indicator of health.
While much is known about hyperglycemia in patients with or at risk for cancer
(Giovannucci et al., 2010; Hammer et al., 2019), the impact of glycemic variability in patients
with solid tumor malignancies has not been well studied and represents a critical knowledge
gap. Stability of glucose is important in hospitalized patients and those receiving care in the
ambulatory setting (American Diabetes Association, 2020a; American Diabetes Association,
2020b). Hemoglobin A1c (HbA1c), an average blood glucose measure that captures glucose
molecules bound to hemoglobin in erythrocytes over 2-3 months (American Diabetes
Association, 2020b), may be unreliable in individuals with cancer because of the influence of the
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disease and the effect of chemotherapy on erythrocyte integrity (Campbell et al., 2019; Fayyaz
et al., 2019; Gu et al., 2018). Yet, HbA1c remains the most widely used test to assess glycemic
control in patients with T2D and cancer. The recommendation for glycemic control in
nonpregnant adults is a HbA1c of <7% (53 mmol/L) (American Diabetes Association, 2020). The
assessment of glycemic variability, unlike HbA1c, takes into account episodes of hypoglycemia
and hyperglycemia. Glycemic variability is an indicator of homeostatic disequilibrium. The
frequency and rate of glucose fluctuations may be used as a marker of metabolic instability
(Kovatchev, 2019). This dissertation challenges the status quo by reporting glycemic variability
with standard deviation (SD) and % coefficient of variation (CV) as measurements of glycemic
control in patients with colon cancer. The findings will inform future research and promote the
evaluation of glycemic variability in patients with cancer.
Recent advances in understanding how to measure glycemic variability offer an
opportunity to study the effects of glucose excursions in patients with cancer. There are
numerous methods of reporting glycemic variability but only two methods, SD and CV, have
published suggestions of high cut-point values to differentiate low and high variability. A
suggested reference range of glycemic variability in an individual who is normoglycemic without
obesity is an SD of 11.5-18 mg/dL and a CV of 12-18% (Salkind et al., 2014). An SD of >29 mg/dL
of glucose has been reported as the level at which glycemic variability increases the risk of
adverse events in patients with hematologic cancers (Hammer et al., 2009). To establish
consistency, the value of 36%CV, computed by %: (SD÷Mean)x100 was recently adopted by the
Advanced Technologies & Treatments for Diabetes (ATTD) organization as a level that separates
stable and unstable glycemic control in patients with T2D using a continuous glucose monitoring
system (CGMS) (Ceriello et al., 2019; Danne et al., 2017; Kovatchev, 2019; Monnier et al., 2018).
The CGMS allows for assessment of extent of glucose extremes and the rate of glucose
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excursions, two important factors when measuring glycemic variability (Kovatchev, 2019). The
amplitude of glucose excursions in patients with cancer is not fully understood and there are not
specific guidelines for glycemic control in this patient population.
Colon cancer is the fourth most commonly diagnosed cancer in the U.S. with an
estimated 104,610 new cases expected to be diagnosed in 2020 (American Cancer Society,
2020). Known associations exist between colon cancer and metabolic syndrome (Bowers et al.,
2006), insulin resistance (Fujihara et al., 2012), and challenges with adherence of T2D
medications (Zanders et al., 2018). These associations support the rationale to study glycemic
variability in patients receiving treatment for colon cancer (Fujihara et al., 2012). Sugar-sensing
neuronal activity that takes place along the gastrointestinal (GI) tract, known as glucosensing
(Fournel et al., 2016), may become altered in the setting of GI cancer and result in difficulty
establishing glycemic regulation. Despite the higher rates of T2D and the known complications
in patients with colon cancer, specific glycemic control guidelines for patients with T2D and
colon cancer have not been developed. This may be because cancer care has traditionally been
siloed from primary care and other specialties such as endocrinology. Multidisciplinary oncology
teams that include endocrinology can advance research and identify reliable and valid methods
of assessing glycemic control in patients with cancer.
Patients with cancer commonly have comorbidities, such as T2D. The study provides
oncology nurses and members of the interdisciplinary healthcare team with information on the
presence of glycemic variability in patients with colon cancer. The study examines the
associations of glycemic variability with demographic and clinical characteristics, cancer
treatment including surgery and chemotherapy, number of chemotherapy cycles completed,
and positive blood cultures for infections. Studies of glycemic variability as an assessment of
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glycemic control in patients receiving treatment for cancer are needed to help inform oncology
research and practice.
Concepts
The main outcome variable of this dissertation was glycemic variability. The study
addressed the following additional concepts: Demographic and clinical characteristics; diabetes
(Type 2 Diabetes, T2D); glycemic state; treatment; chemotherapy details; and positive blood
cultures for infections.
Glycemic Variability
Glycemic variability was measured by standard deviation (SD) and % coefficient of
variation (CV) and was calculated using all available blood glucose values within 15 months of
the date of colon cancer surgery. A variety of methods of calculating glycemic variability exist,
including mean amplitude of glycemic excursions (MAGE) and mean absolute glucose change
(MAG), and continued debate remains about the clinical utility of glycemic variability
(Kovatchev, 2019). Glycemic variability can be reported by short-term (within-day/between-day)
and long-term (visit-to-visit) measurements (Ceriello et al., 2019). The numerous methods of
reporting glycemic variability, most without a known high cut-point value, have contributed to
the uncertainty of its utility (Kovatchev, 2019). This study employed the use of SD and CV to
measure glycemic variability as these methods have suggested cut-point values that delineate
low and high glycemic variability (Ceriello et al., 2019; Hammer et al., 2009). SD of glucose from
the mean was calculated using a macro with SPSS 26 (IBM Corporation, Armonk, NY, USA;
2017). CV of glucose was computed using the following, consistently used formula %:
(SD÷Mean)x100 (Ceriello et al., 2019; Monnier et al., 2018).
Meta-analyses have reported associations between glycemic variability, independent of
HbA1c values with vascular complications (Gorst et al., 2015), progression of diabetic
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nephropathy (Cheng et al., 2014), and with mortality (Gorst et al., 2015). Glycemic variability
was found to be associated with a greater risk of developing end stage renal disease in patients
with T2D (Yang et al., 2015) and cognitive decline in elderly patients without T2D (Yu et al.,
2020). Glycemic variability was also recently reported to be an independent predictor of
mortality in patients with congestive heart failure (Gu et al., 2018), increased mortality in
critically ill and hospitalized patients (Singh et al., 2018), and higher 30 day mortality following
general surgery (Akirov et al., 2019).
Consistent findings of associations between glycemic variability and poor outcomes
have been reported in studies of patients with hematological cancers. In 1,175 patients with
hematological cancer, higher glycemic variability within 100 days following allogeneic
hematopoietic cell transplant was associated with twice the risk of infection and as much as a
14.5-fold higher risk of 200 day non-relapse mortality with a SD of > 90 mg/dL (Hammer et al.,
2009). Lower remission rates and reduced survival in patients with Acute Myelogenous
Leukemia (AML) were found to be associated with increased glycemic variability during
induction chemotherapy (Kuhlman et al., 2019). Two recent studies identified that glycemic
variability, measured by SD and CV, was associated with increased risk of future cancer
development in healthy adults with and without T2D (Kobayashi et al., 2020; Saito et al., 2019).
To begin to close the critical research gap, this dissertation study used the electronic
health record (EHR) to investigate glycemic variability in patients with stage II-III colon cancer
within one year following surgery. Additional concepts addressed in this dissertation study are
described below.
Demographic and Clinical Characteristics
Demographic factors included: age, gender, body mass index (BMI), race, socioeconomic,
marital status, employment status, and median household income. Clinical characteristics
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included: cancer stage, date of cancer surgery, prescription T2D therapy, cumulative
corticosteroid dose, and neutrophil-to-lymphocyte ratio.
Type 2 Diabetes
Type 2 Diabetes (T2D) was identified as ICD-CM-10 codes of E08-E13 as listed on the EHR
problem list. The principal investigator (PI) also searched the surgery notes and anesthesia
records on all patients with either 1) a preoperative glucose of > 140 mg/dL, the defined value of
hyperglycemia in hospitalized patients (American Diabetes Association, 2020a) or 2) T2D
therapy documented in the EHR at the time of surgery.
Glycemic State
Preoperative and pre-chemotherapy glycemic state was defined as normoglycemia (random
glucose levels in the range of 70-140 mg/dL); hypoglycemia (glucose levels <70 mg/dL); and
hyperglycemia (glucose levels > 140 mg/dL) .
Treatment
Date of colon cancer surgery and date of first chemotherapy treatment administration
were recorded.
Chemotherapy Details
The standard of care for high-risk stage II and stage III colon cancer is surgery followed by
curative intent adjuvant chemotherapy (National Comprehensive Cancer Network, 2020) . The
following information was recorded: chemotherapy regimen, names of antineoplastic agents,
administration dates, and total number of adjuvant chemotherapy cycles administered. The
dates of chemotherapy administration were used to identify the timing of cycle 1, 4, 8, and 12.
Chemotherapy doses were retrieved and used to identify chemotherapy dose reductions.
Treatment delays and date of the last cycle of chemotherapy were recorded.
Positive Blood Cultures
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Blood stream infections were captured by retrieval of all positive blood culture results.
Theoretical Framework
The conceptual model used to guide this dissertation study was derived from the
Malglycemia Orbit Model (Figure 1) (Hammer & Voss, 2012). The Malglycemia Orbit Model was
used to support dissertation research of malglycemia in patients with AML (Storey, 2015). The
Malglycemia Orbit Model includes three paired orbits: 1) malglycemia and normal blood
glucose, 2) cancer and treatment, and 3) impaired immune function and infection. The three
paired variables influence, and are influenced by, patient characteristics. The core elements of
the model reflect the individual patient characteristics of genetic, epigenetic, lifestyle, and
comorbidities. The outcomes described by the model include survival or death. The model
provides the first visual description of the influence that malglycemia (hypoglycemia,
hyperglycemia, glycemic variability) can have on multiple factors in individuals with cancer. A
physiological model offered additional support by describing the numerous cellular pathways
that contribute to and are impacted by hyperglycemia in patients with cancer (Hammer et al.,
2019).
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Figure 3: The Malglycemia Orbit Model.
Note. MAL=malglycemia, INF=infection, TX=treatment, NBG=normal blood glucose,
IMM=impaired immune function. Used with permission from the Oncology Nursing
Society. (Hammer & Voss, 2012)
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The derived model used to guide this dissertation research (Figure 2) represents
the associations between demographic and clinical factors and glycemic variability; the
presence of glycemic variability in patients receiving cancer treatment; the associations
between baseline diabetes and glycemic state and glycemic variability; and the
association between glycemic variability and number of chemotherapy cycles completed
and/or number of bloodstream infections.

Figure 4: Conceptual Model for Glycemic Variability in Patients with Stage II-III Colon
Cancer.
Note. Derived from The Malglycemia Orbit Model (Hammer & Voss, 2012)
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Summary
The purpose of this dissertation was to examine glycemic variability within one year
among adult patients treated with surgery with or without (+/-) chemotherapy for stage II-III
colon cancer. Following a feasibility study in summer 2019, the Specific Aims were revised to
include patients with stage II and III colon cancer and compare groups of patients with and
without T2D. This dissertation has been prepared using the three manuscript format. Chapter 2
provides a published integrative review that investigates the presence and methods of
reporting glycemic variability in patients with GI cancers during and following treatment.
Chapter 3 contains the manuscript of Aims 1, 2, 3, and the Exploratory Aim and investigates
glycemic variability within one year among adult patients, with and without T2D, treated with
surgery for stage II-III colon cancer. Chapter 4 provides results of Aims 1, 4, 5, and the
Exploratory Aim and examines glycemic variability within one month following surgery,
throughout adjuvant chemotherapy, and within one year following surgery among adult
patients, with and without T2D, treated for stage II-III colon cancer. The neutrophil-tolymphocyte ratio (NLR) was investigated as a clinical characteristic in patients in this
dissertation; findings will be reported in a future publication. Chapter 5 contains a summary of
the findings and discusses implications for practice and future research.
Purpose and Specific Aims
The purpose of this descriptive, correlational, retrospective, longitudinal pilot medical
record study was to examine glycemic variability within one year among adult patients treated
with surgery with or without (+/-) chemotherapy for stage II-III colon cancer.
Aims:
1. Among patients with stage II-III colon cancer (n=165), +/- type 2 diabetes (T2D), treated
with surgery +/- chemotherapy, describe associations between glycemic variability and
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patient demographic (i.e., gender, age, body mass index, race, socioeconomic,
employment, insurance, marital status) and clinical factors (i.e., stage of cancer, date of
colon cancer surgery, prescription T2D therapy, cumulative steroid dose, neutrophil-tolymphocyte ratio) within the first month and within one year following surgery.
2. Describe glycemic variability using all clinical glucose measurements in patients with
stage II-III colon cancer (n=165), +/- T2D, +/- chemotherapy, within the first month and
within one year following surgery.
3. Determine glycemic variability within the first month and within one year following
surgery among patients with stage II-III colon cancer (n=165), +/- T2D, treated with
surgery +/- chemotherapy.
4. Determine glycemic variability within the first month following surgery to glycemic
variability between cycle 1 and cycles 4, 8, and 12 of chemotherapy in patients with
stage II-III colon cancer, +/- T2D, who received surgery +/- chemotherapy (n=58).
5. Analyze associations between T2D status, preoperative glycemic state, and prechemotherapy glycemic state with glycemic variability between cycle 1 and cycles 4, 8,
and 12 of chemotherapy and within one year following surgery in patients with stage IIIII colon cancer treated with surgery + chemotherapy (n=58 ).
•

Exploratory Aim:
Examine associations between glycemic variability, the type of chemotherapy
prescribed, they type of chemotherapy administered, the number of
chemotherapy cycles completed, and the occurrence of bloodstream infections
within the first month following surgery, during chemotherapy treatment, and
within one year following surgery in patients with stage II and III colon cancer
(n=165; n=58) +/- T2D.
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Patients with stage II-III colon cancer were selected as the target population for the
study because the treatment objective is cure. Patients with stage II-III colon cancer, unless
determined to be medically unfit for surgery, are treated with surgical resection of the tumor.
Chemotherapy is the current standard of care treatment to improve survival for patients with
stage III colon cancer (American Cancer Society, 2020; National Comprehensive Cancer Network,
2020) . Chemotherapy is most commonly used for patients with stage III or metastatic colon
cancer; however, approximately 20% of patients with stage II colon cancer receive
chemotherapy for high-risk disease (Casadaban et al., 2016; Ejaz et al., 2017; O'Connor et al.,
2011).
This study supports the research priorities of the Oncology Nursing Society (ONS) which
emphasizes the importance of precision health and biosignature research (Von Ah et al., 2019).
Nursing care for patients with colon cancer currently uses a one-size-fits all approach with
standard chemotherapy education and routine nursing practices. Precision health and
biosignature research, such as glycemic variability research, provides evidence needed to
support personalized nursing interventions for patients with cancer who have high glycemic
variability. The findings of this dissertation provide the first report of glycemic variability and
associations between glycemic variability, demographic and clinical characteristics,
chemotherapy, number of chemotherapy cycles completed, and occurrence of positive blood
cultures in patients with stage II – III colon cancer, with and without T2D. The study informs
future research on glycemic variability in patients with colon cancer.
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CHAPTER 2: MANUSCRIPT #1
Glycemic Variability in Patients with Gastrointestinal Cancer: An integrative review

European Journal of Oncology Nursing : The Official Journal of European Oncology Nursing
Society, 48, 101797. https://S1462-3889(20)30077-6 [pii]
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Abstract
Purpose: Glycemic variability is associated with risks for adverse events in patients with cancer.
Several studies have evaluated the presence and impact of hyperglycemia and/or hypoglycemia
in patients with cancer; however, few studies have evaluated glycemic variability. The purpose
of this integrative review of studies in patients with gastrointestinal cancers was to investigate
the presence and methods of reporting glycemic variability during and following treatments.
Methods: A comprehensive review of the literature was conducted. PubMed, CINAHL, EMBASE,
and Cochrane databases were searched for publications between 1/1/1969 and 7/24/2019.
Studies of patients with gastrointestinal cancer following surgery, during treatment, and < 5
years following treatment were included and evaluated by cancer type and method of glucose
and glycemic variability measurement.
Results: Among 1526 patients with gastrointestinal cancer across 19 studies, gastric and
pancreatic cancers were most prevalent. Timing of glucose testing and methods of analyzing
glycemic variability varied. Most analyses used the standard deviation or interquartile range.
Glycemic variability was more prevalent among patients with Type 2 Diabetes and among those
with pancreatic cancer. In some patients glycemic variability remained notable > one year
following surgery despite improvements in glycemic control.
Conclusion: Patients with gastrointestinal cancer experience glycemic variability during and up
to one year following treatment. There was heterogeneity in methods related to timing of
testing and reporting glycemic variability among the 19 studies in this review. Future
investigations need to identify the presence and define the methods of measuring glycemic
variability in patients with gastrointestinal cancer.
Keywords: blood glucose, cancer treatment, gastrointestinal cancer, glycemic variability,
measurement
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Glycemic Variability in Patients with Gastrointestinal Cancer: An integrative review
Incidence of Gastrointestinal Cancer and Type 2 Diabetes
Over 1.7 million people were expected to be diagnosed with cancer in the United States
(US) in 2019, including more than 319,000 cases of gastrointestinal (GI) cancer (American
Cancer Society, 2019). Two factors that increase the risk for GI cancer (e.g., colorectal,
pancreatic, hepatocellular, and intrahepatic cancers) are metabolic syndrome and insulin
resistance (Andersen et al., 2017; Bowers et al., 2006; Fujihara et al., 2012). Metabolic
syndrome includes a cluster of metabolic abnormalities including fasting hyperglycemia (a
diabetes diagnostic factor), abdominal obesity, high triglycerides, low high-density lipoprotein
cholesterol, and high blood pressure (Moore et al., 2017). Independent of metabolic
syndrome, Type 2 Diabetes (T2D) and insulin resistance increase the risk for GI and other
cancers (Giovannucci et al., 2010). In addition to T2D being a risk factor for the diagnosis of
pancreatic cancer, pancreatic cancer can contribute to the development of T2D (Andersen et
al., 2017).
Depending on the type of cancer, up to 29% of patients have pre-existing T2D; notably
higher than the 12% prevalence of T2D in the general population (Barone et al., 2010). By 2050
up to 28% of the US population is expected to have T2D (Centers for Disease Control &
Prevention, 2017). As the incidence of T2D increases and the number of patients with cancer
rises, the number of patients with concurrent T2D and cancer will increase. In addition,
individuals with a dual diagnosis of cancer and T2D have higher rates of morbidity and mortality
compared to patients with cancer who do not have T2D (Bella et al., 2013; Dehal et al., 2012).
Individuals with or without T2D undergoing treatment for cancer can experience perturbations
in glycemic levels that increase the risk for adverse events such as infection and death (Derr et
al., 2008; Hammer et al., 2009). Oncology nurses and advanced practice providers should be
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aware of the risks and challenges that patients with T2D may experience. Collectively termed
malglycemia, these perturbations can include hyperglycemia (blood glucose of >126 mg/dl),
hypoglycemia (blood glucose of < 70 mg/dl), and/or glycemic variability (GV) (standard deviation
(SD) between blood glucose measurements at a level of >29 mg/dl) (Hammer et al., 2009).
More studies have evaluated the effects of hyperglycemia and/or hypoglycemia in
patients with cancer than those that have evaluated GV. A number of studies found that
hyperglycemia was associated with toxicities (Fuji et al., 2007; Gebremedhin et al., 2013; Jun et
al., 2013), infections (Derr et al., 2008; Hammer et al., 2009; Margonis et al., 2017; Storey & Von
Ah, 2016; Vilar-Compte et al., 2008), treatment interruptions (Hershey & Hession, 2017), nonrelapse mortality (Hammer et al., 2009), increased cancer recurrence (Jun et al., 2013) and
increased mortality (Fuji et al., 2007; Jun et al., 2013; Okamura et al., 2017; Pidala et al., 2011;
Villarreal-Garza et al., 2012; Vu et al., 2012).
Given the challenges with metabolic syndrome (Bowers et al., 2006), insulin resistance
(Fujihara et al., 2012), and T2D management (Zanders et al., 2018), patients with GI cancer are a
logical population for investigation of GV. Sugar-sensing neuronal activity that takes place along
the GI tract, known as glucosensing (Fournel et al., 2016), may become altered in the setting of
GI cancer and result in difficulty with glycemic regulation. Managing malglycemic episodes,
particularly GV, can be challenging in patients with or without T2D receiving treatment for
cancer.
Glycemic Control and Variability in Patients With Cancer
Glycemic control guidelines exist for patients with critical illness and for patients
following surgery (Garber et al., 2019), but no specific guidelines exist for patients with cancer.
The American Academy of Clinical Endocrinologists and American College of Endocrinology
define glycemic control for patients with T2D in the general population as a glycosylated
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hemoglobin A1c (HbA1c) of <6.5%, but recognize that a higher range of HbA1c may be more
appropriate for older patients and those at risk of hypoglycemia (Garber et al., 2019). The
sudden turnover of erythrocytes due to acute blood loss and the apoptotic effect of
chemotherapy affects HbA1c levels, making it an unreliable assessment of glycemic control in
patients with cancer (Campbell et al., 2019; Fayyaz et al., 2019).
Consensus guidelines acknowledge that HbA1 has limitations as it varies by
race/ethnicity and by comorbidities (Garber et al., 2019). Although HbA1c is a common
measurement in patients with T2D, sequential glucose measurements over time may provide a
more accurate assessment in patients with cancer receiving chemotherapy. New
recommendations include considerations for use of professional continuous glucose monitoring
in patients who are having difficulty achieving their target goal, in patients on intensive insulin
therapy, those with hypoglycemia unawareness, or those with frequent episodes of
hypoglycemia (Garber et al., 2019). GV can conveniently be calculated from continuous glucose
monitors and incorporated into glycemic control guidelines.
Currently, clinical guidelines for the best measure of GV have not been established and
interpretations of findings have been inconsistent. The value of 36%CV (coefficient of variation),
computed by SD of glucose/mean glucose x 100, can be used to differentiate between stable
and unstable glycemic control in patients with T2D using a continuous glucose monitor
according to the Advanced Technologies & Treatments for Diabetes (Danne et al., 2017;
Monnier et al., 2018). In addition to %CV (Danne et al., 2017; Monnier et al., 2018), the use of
SD (Rodbard, 2009), interquartile range (IQR) (Service et al., 1970), mean amplitude of glycemic
excursions (Service et al., 1970), mean of daily differences (Molnar et al., 1972), continuous
overall net glycemic action (McDonnell et al., 2005), average daily risk range (Patton &
Clements, 2013), low blood glucose index and high blood glucose index (Kovatchev et al., 1997),
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mean absolute glucose (Kohnert et al., 2013), ambulatory glucose profile (Johnson et al., 2019),
and visit to visit changes (measures of variability between sequential visits) (Tang et al., 2019)
have been used to capture GV. Although less frequently used, the standard error of mean (SEM)
has often been used interchangeably with SD; however, SEM is most appropriately used to
create confidence intervals and to describe the certainty of the mean (Barde & Barde, 2012).
Aside from inconsistencies in evaluating GV in the general population, studies of GV in
patients with cancer are even more limited and inconsistent. Among the investigations to date,
a study published in 2019 reported that patients with T2D and higher levels of GV developed
cancer at an increased rate compared to patients with lower GV and suggested that GV may be
associated with oncogenesis (Saito et al., 2019). A decade earlier, a study reported that all three
malglycemic states (e.g., hyperglycemia, hypoglycemia, GV) in patients treated with allogeneic
hematopoietic cell transplantation increased the risk of infection and mortality, but GV carried
the greatest risk (Hammer et al., 2009). With only a few published studies over a decade,
oncology nurses and advanced practice providers have a limited understanding of the GV
experienced in patients with cancer. The purpose of this integrative review of studies in patients
with GI cancers was to investigate the presence and methods of reporting GV during and
following treatments. The review questions were:
•

Do patients with gastrointestinal cancer experience GV during and following
treatment?

•

What methods are used to report GV in patients with gastrointestinal cancer?
Methods

Data Sources and Searches
The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA)
guidelines (Liberati et al., 2009) were followed. An electronic search was conducted of all
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published, peer-reviewed literature in PubMed, CINAHL, EMBASE, and Cochrane between
1/1/1969 and 7/24/2019. Retrieved articles over the last 50 years allowed for data to be
captured from studies conducted seven years prior to the introduction of HbA1c as a measure of
glycemic control. GI cancers were defined using the World Health Organization (WHO) classified
digestive cancers: esophageal, stomach, small intestine and ampulla, appendix, colon and
rectum, anal canal, liver and intrahepatic bile ducts, gallbladder and extrahepatic bile ducts,
pancreas, hematolymphoid tumors of the digestive system, and mesenchymal tumors of the
digestive system cancers (WHO Classification of Tumours Editorial Board, 2019). Key search
terms included: blood glucose, blood sugar, blood glucose control, glycemic variability,
malglycemia, neoplasms, cancer, malignancy, drug therapy, radiotherapy, radiation therapy,
chemotherapy, surgical procedures, and operative surgical procedures. Article selection was
limited to: English language, humans, and age >19 years. Population, Interest, and Outcome
(PIO) search terms are reported in Supplementary Table 1.
Study Selection
Studies that reported glucose or HbA1c measurements with a reported measure of GV
(e.g., SD, SEM, IQR) during the peri-operative phase, and/or during cancer treatment, and up to
5 years following completion of cancer treatment were included. For the purposes of this
review, we used the term “acute measurements” of GV for glucose levels that included SD, SEM,
or IQR to determine GV and “chronic measurement” for levels associated with HbA1c. Patients
with any stage of GI cancer were included. Treatments were limited to surgery, radiation
therapy, and/or systemic therapy (e.g., chemotherapy, targeted therapy, immunotherapy).
Studies were excluded if the patients’ glucose assessments were not available at baseline,
occurred only one time, and occurred only in the intra-operative setting up to four days
following surgery. Studies were also excluded if a GV measurement was not included within the
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published results. The first (N.M.) and second author (A.B.) participated in the literature search
process. Following the PRISMA guidelines, the first author retrieved search results and
summarized the data under the guidance of the 2nd and 3rd authors (A.B., M.H.).
Data Extraction and Quality Assessment
Figure 1 details the search results. The initial search yielded 1038 articles, with 20
additional articles identified manually. Titles and abstracts were screened, and duplicates were
removed. Based on the criteria, a total of 978 articles were excluded leaving a total of 19 articles
eligible for analysis.
Following the PRISMA guidelines (Liberati et al., 2009), a table of evidence was
developed (Table 1). Data quality was assessed based on the quality metrics summarized by
Conn & Rantz. Table 1 describes the quality scores based on study strengths and limitations.
Quality scores ranged from one to five, with five indicating the highest quality (Conn & Rantz,
2003). Criteria for quality scoring included rigorous sample selection, recruitment strategy,
adequacy of sample size, randomization, comparison group, blinding, interventions, attrition
management, outcome measures, and statistical analysis. The mean score of the articles
included in this analysis (n=19) was 3.26, indicating a moderate strength of quality overall.
Studies included patients with various types of GI cancer, with some including cohorts of
patients based on their type of cancer. In order to report GV and provide standardized
comparisons, studies that reported glucose levels in mmol/L were converted to mg/dL (mmol x
18 = mg/dL).
Results
Our purpose was to investigate the presence and methods of reporting GV during and
following treatment in patients with GI cancers.
Study Characteristics
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Study characteristics are shown in Table 2. A total of 2518 patients were included
among the 19 studies, which represented patients with (n=1526) and without cancer (n=992).
Nine studies included patients with gastric cancer (An et al., 2013; Cao et al., 2011; Choi et al.,
2017; Gemici et al., 2013; Kandaz et al., 2017; Sagor et al., 1981; Shen et al., 2015; Yoshikawa et
al., 2012; Zhang et al., 2013; Zhu et al., 2013). Pancreatic cancer (Nakamori et al., 1999; Pannala
et al., 2008; Shi et al., 2017) and esophageal cancer (Miholic et al., 1993; Xiao-Bo et al., 2014;
Zhao et al., 2014) were the focus of three studies each, and one study included patients with
both colon and rectal cancers (Long et al., 1990). Three other studies included patients with a
variety of GI cancers (Lundholm et al., 2010; Sohn et al., 2018; Yoshikawa et al., 2012). Sample
sizes ranged from 15 to 1445 patients; the largest study included 512 patients with pancreatic
cancer (Pannala et al., 2008). Six of the studies were randomized controlled trials (Cao et al.,
2011; Choi et al., 2017; Lundholm et al., 2010; Xiao-Bo et al., 2014; Zhao et al., 2014; Zhu et al.,
2013) and the remaining 13 studies were retrospective designs or small prospective case-control
studies.
Patients were represented from different geographic locations including the US
(n=1460), Asia (n=907), and Europe (n=151). Mean age across studies ranged from 55 to 74.5
years and mean Body Mass Index, reported among 84% of the patients, ranged from 20.8 to
28.4 kg/m2. The majority of patients had pancreatic (n=700) or gastric (n=559) cancer. Stages of
cancer varied across the studies. Patients receiving curative intent treatment for earlier stages
of cancer were included in studies that evaluated the effect of surgery on glycemic control. GV
was reported by various methods (e.g., SD, SEM, IQR), but was not a primary focus in any of the
studies.
Glucose Measurements
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Types of glucose measurements used, fasting status, and methods of reporting GV are
shown in Table 2. Laboratory or point-of-care peripheral blood glucose testing was the most
commonly reported glucose measurement and SD was the most common method of reporting
GV. Notably, no studies reported %CV. Studies that reported HbA1c also included baseline
glucose.
Of the eleven studies that reported glucose or HbA1c with SD, six reported acute (Cao et al.,
2011; Nakamori et al., 1999; Pannala et al., 2008; Shen et al., 2015; Xiao-Bo et al., 2014;
Yoshikawa et al., 2012) and five acute/chronic levels (An et al., 2013; Choi et al., 2017; Gemici et
al., 2013; Kandaz M. et al., 2017; Shi et al., 2017). Three studies reported glucose or HbA1c with
IQR, including two acute (Zhao et al., 2014; Zhu et al., 2013) and one acute/chronic levels (Sohn
et al., 2018). Five studies reported glucose or HbA1c with SEM, including four acute (Long et al.,
1990; Lundholm et al., 2010; Miholic et al., 1993; Sagor et al., 1981) and one acute/chronic
levels (Zhang et al., 2013). Glucose and HbA1c levels were measured at various times across the
studies as shown in Table 3. All studies included a baseline glucose or HbA1c level, most often
preoperatively, and a measurement at one or more of the following time points: postoperative
day >4, or at 3, 6, 9, and 12 months following the baseline value.
Cancer Treatments
Studies varied by the type of cancer treatment or medical therapy that were evaluated
in relation to glucose levels. Most of the studies (73%) reported the effect of surgery on glucose
levels (An et al., 2013; Choi et al., 2017; Long et al., 1990; Miholic et al., 1993; Nakamori et al.,
1999; Pannala et al., 2008; Sagor et al., 1981; Shen et al., 2015; Shi et al., 2017; Sohn et al.,
2018; Xiao-Bo et al., 2014; Yoshikawa et al., 2012; Zhang et al., 2013; Zhao et al., 2014). Two of
these studies also evaluated the effect of total parenteral nutrition (TPN) on postoperative
glucose metabolism (Long et al., 1990; Xiao-Bo et al., 2014). Few studies evaluated the effect on
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glucose levels from chemotherapy and radiation (chemoradiation) (Gemici et al., 2013; Kandaz
M. et al., 2017), ghrelin (Lundholm et al., 2010), analgesia (Zhu et al., 2013), or insulin (Cao et
al., 2011).
Only six (32%) of the studies included patients who received chemotherapy (Choi et al.,
2017; Gemici et al., 2013; Kandaz M. et al., 2017; Pannala et al., 2008; Sohn et al., 2018; Zhao et
al., 2014). Two of these studies evaluated the effect of chemoradiation on glucose levels in
patients following curative intent gastric cancer resection (Gemici et al., 2013; Kandaz M. et al.,
2017). Only one study included the details of chemotherapy medications, dosing, or timing of
administration and analyzed the association between chemotherapy and glycemic control
(Kandaz M. et al., 2017).
Baseline Glycemic States
GV at baseline and one year following treatment are shown in Figure 2. Baseline mean
glucose levels ranged from 86.4 -178 mg/dL with repeat assessments ranging from 82.45 to
145.8 mg/dL up to one year later. Baseline HbA1c levels across studies ranged between 5.397.6% and follow-up levels ranged between 5.5-7.1% from one month to one year following
surgery. Baseline HbA1c levels in patients with T2D were highest in patients with gastric cancer
(7.6 +/- 1.2%) (Choi et al., 2017).
A total of 676 (27.6%) patients across 10 studies were identified as having T2D at
baseline (An et al., 2013; Cao et al., 2011; Choi et al., 2017; Nakamori et al., 1999; Pannala et al.,
2008; Shen et al., 2015; Shi et al., 2017; Sohn et al., 2018; Yoshikawa et al., 2012; Zhang et al.,
2013), but not all studies reported whether or not patients had T2D. In three studies that
reported duration of T2D prior to the diagnosis of cancer, one reported a range of zero to nine
years (Zhang et al., 2013) and the others reported a mean/median of 5.5-6.6 years (An et al.,
2013; Cao et al., 2011). Two additional studies collected history and duration of diabetes
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categorically as 1) new onset, defined as T2D <2 years prior to a cancer diagnosis, or 2)
chronic/long-lasting, defined as >2 years prior to a cancer diagnosis (Pannala et al., 2008; Sohn
et al., 2018). New onset diabetes was more frequent (62-74%) than chronic/long lasting T2D
(26-38%) (Pannala et al., 2008; Sohn et al., 2018).
Only four of the 10 studies that included patients with T2D reported the type of
prescribed T2D control therapy (An et al., 2013; Cao et al., 2011; Choi et al., 2017; Shen et al.,
2015). Among these studies, oral T2D medications were used in 12.2% to 93.7% of patients and
insulin therapy was used in 0.5% to 65% of patients. Three studies reported changes in T2D
medication use following gastric surgery (An et al., 2013; Choi et al., 2017; Shen et al., 2015).
One study reported that up to 25% of patients stopped oral T2D therapy 21 days following
surgery (Shen et al., 2015). Two other studies reported that between 5-8% of patients (Choi et
al., 2017) to 25% (An et al., 2013) stopped T2D therapy one year following gastric cancer
surgery.
Glycemic Control
Glucose and HbA1c levels were evaluated to determine glycemic control (Table 4).
Among the 10 studies that included patients who had T2D (An et al., 2013; Cao et al., 2011; Choi
et al., 2017; Nakamori et al., 1999; Pannala et al., 2008; Shen et al., 2015; Shi et al., 2017; Sohn
et al., 2018; Yoshikawa et al., 2012; Zhang et al., 2013), six found that glucose levels following
surgery improved in patients with gastric and pancreatic cancer (An et al., 2013; Pannala et al.,
2008; Shen et al., 2015; Sohn et al., 2018; Zhang et al., 2013; Zhu et al., 2013). Chronic/longstanding T2D was associated with poorer survival (p=.004) and poor glycemic control following
pancreatectomy (p=.031) (Shi et al., 2017).
Two studies reported glycemic control and GV in relation to nutritional therapy around
the time of cancer surgery (Long et al., 1990; Xiao-Bo et al., 2014). One study found that the use
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of TPN after colorectal cancer surgery resulted in a higher mean glucose level on the fifth
postoperative day compared to baseline (144.6 mg/dL +/- 12.3 SEM vs 140.9 mg/dL +/- 16.4
SEM) (Long et al., 1990). In a separate study of patients with esophageal cancer treated with
esophagectomy, glucose was more tightly controlled with enteral nutrition (135 mg/dL +/- 7.2
SD) compared to those with parenteral nutrition (181.8 mg/dL +/- 10.8 SD (p<.05) eight days
following surgery (Xiao-Bo et al., 2014).
Four studies (Miholic et al., 1993; Nakamori et al., 1999; Sagor et al., 1981; Yoshikawa et
al., 2012) conducted oral glucose tolerance tests following surgery. Out of 36 patients with
periampullary cancers (included pancreatic, ampullary, duodenal, bile duct, malignant endocrine
carcinoma, and colon cancer), 15 patients had normal oral glucose tolerance tests prior to
surgery. Of these 15 patients, 40% (n=6) were classified as having borderline diabetes following
surgery (Yoshikawa et al., 2012). In 15 patients that had T2D before surgery, seven improved to
normal or borderline T2D status following surgery (Yoshikawa et al., 2012). Two studies
demonstrated that patients with gastric (Sagor et al., 1981) and esophageal (Miholic et al., 1993)
cancer without T2D experienced a more rapid rise in glucose levels with an oral glucose
tolerance tests compared to patients without cancer. Patients with pancreatic cancer had a
slightly delayed response to their oral glucose tolerance tests compared to patients without
cancer, however proinsulin levels were higher in the patients with cancer (Nakamori et al.,
1999).
In a study that investigated an intensive insulin therapy intervention in patients with
T2D following radical gastrectomy, significantly fewer postoperative complication rates were
observed with intensive insulin therapy (7.6%) compared to conventional insulin therapy (18.4%,
p=.031) (Cao et al., 2011). Significantly shorter duration of antibiotic use, days to suture
removal, and shorter length of hospital stay (p<.001, p<.001, and p=.002 respectively) were
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observed with intensive insulin therapy (Cao et al., 2011). Patients treated with intensive insulin
therapy compared to those who received conventional insulin therapy had decreased
postoperative mortality, however the results did not reach statistical significance (4.3% vs 5.7%,
p=.742) (Cao et al., 2011).
Glycemic Variability
Studies that included patients with T2D reported wider ranges of GV (An et al., 2013;
Cao et al., 2011; Choi et al., 2017; Nakamori et al., 1999; Pannala et al., 2008; Shen et al., 2015;
Shi et al., 2017; Yoshikawa et al., 2012; Zhang et al., 2013). Mean glucoses and SDs were higher
in patients with pancreatic cancer (Nakamori et al., 1999; Pannala et al., 2008; Shi et al., 2017;
Sohn et al., 2018) compared to those with gastric cancer (An et al., 2013; Cao et al., 2011; Choi
et al., 2017; Gemici et al., 2013; Kandaz M. et al., 2017; Sagor et al., 1981; Shen et al., 2015;
Zhang et al., 2013; Zhu et al., 2013). Patients with pancreatic cancer treated with surgery had
glucose levels of 116-174.2 mg/dL and SDs of 48-60 mg/dL before surgery followed by glucose of
120-167 mg/dL and SDs as high as 94 mg/dL three months following surgery (Pannala et al.,
2008; Shi et al., 2017). Two studies reported improvements in fasting glucose following
pancreatectomy (Pannala et al., 2008; Sohn et al., 2018) while one study did not (Shi et al.,
2017).
Patients with gastric cancer had glucose levels between 122.4 and 155.7 mg/dL and SDs
of 10.8 and 18 mg/dL before surgery (An et al., 2013; Cao et al., 2011; Gemici et al., 2013; Shen
et al., 2015; Zhang et al., 2013), while one study reported baseline glucose with IQRs between
75.6 mg/dL and 93.6 mg/dL (Zhu et al., 2013). When assessed within eight days following gastric
cancer surgery, glucose levels between 88.2 and 178.2 mg/dL and SDs between 14.4 and 18
mg/dL were noted (Cao et al., 2011; Zhu et al., 2013). Three months following surgery, glucose
levels were between 87.5 and 136 mg/dL with SDs between 11.4 and 56.6 mg/dL (An et al.,

29
2013; Choi et al., 2017; Kandaz M. et al., 2017; Shen et al., 2015). Glucose levels in patients with
gastric cancer ranged between 90.6 and128 mg/dL with SDs of 11.3 and 38.5 mg/dL six months
following surgery (An et al., 2013; Choi et al., 2017; Gemici et al., 2013; Sohn et al., 2018). One
year following surgery glucose levels were between 82.5 and 130.1 mg/dL with SDs of 10.5-39.1
mg/dL (An et al., 2013; Choi et al., 2017; Gemici et al., 2013; Kandaz M. et al., 2017).
HbA1c levels also varied across studies. The highest levels of GV experienced across
studies was in patients with T2D three months following pancreatectomy (Shi et al., 2017). The
mean glucose level in these patients was 167 mg/dL +/- 94 SD. GV one year following
pancreatectomy continued, though notably with a slightly lower mean glucose level of 142
mg/dL +/- 79 SD (Shi et al., 2017). Patients with pancreatic cancer experienced an increase in
HbA1c from 6.7 +/-1.5% before surgery to 7.3 +/-1.0% three months following surgery. HbA1c
improved to 6.5 +/-0.8% at one year following surgery, which was lower than baseline levels (Shi
et al., 2017).
Postoperative complications were associated with higher postoperative glucose (p=.014)
(Shi et al., 2017). Decreased recurrence free survival and poorer overall survival rates following
pancreatic cancer surgery were associated with high glucose before surgery (p=.045 and 0.016)
and high HbA1c following surgery (p=.010 and 0.011) (Shi et al., 2017). New onset T2D, as
opposed to long-standing T2D, was associated with improved glycemic control and/or complete
resolution of T2D in patients following pancreatic cancer surgery (p=.009) (Pannala et al., 2008).
Similar findings were reported in a study of a mixed sample of patients with both pancreatic and
non-pancreatic GI cancers (p=.021) (Sohn et al., 2018).
In patients with gastric cancer and T2D, HbA1c improved from 7.1 +/- 1.8% before total
gastrectomy to 6.5 +/-1.6% one year following surgery (An et al., 2013). In patients treated with
subtotal gastrectomy with Billroth I or Billroth II anastomosis, HbA1c minimally changed from
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preoperative levels of 7.2 +/-1.1% and 7.3 +/-1.3% respectively to 7.1 +/-0.9% and 7.1 +/- 1.6%
one year following surgery (An et al., 2013).
A study by Gemici et al. (2013) noted trends in HbA1c when comparing baseline levels to
six months and one year following surgery in 53 patients with gastric cancer, without T2D, who
received adjuvant chemotherapy plus radiation therapy (chemoradiation) compared to those
who received no adjuvant therapy. The mean HbA1c levels in the chemoradiation treatment and
control groups at baseline were 5.5 +/- 0.5 % and 5.89 +/- 0.7%. Twelve months following
treatment, the HbA1c remained well controlled with levels of 5.7 +/-0.6% and 6.2 +/- 0.5%.
Similarly, baseline glucose in the chemoradiation treatment group was 92.5 mg/dL +/- 12.2 SD
and was similar to glucose in the control group of 95.1 mg/dL +/- 22.3 SD. One year following
surgery, glucose and SDs decreased to 88.5 mg/dL +/- 10.5 SD in the adjuvant treatment group
and 90.6 mg/dL +/- 18 SD in the control group. No differences were observed between the
groups of patients who received chemoradiation and those who did not, however the sample
size was small (Gemici et al., 2013).
Kandaz et al. (2017) evaluated patients with gastric cancer without T2D for the effect of
chemoradiation on pancreatic volume, glucose, HbA1c, insulin, and lipase. No changes were
noted from baseline in glucose or HbA1c levels at completion of radiation therapy and at one,
three, six, and 12 months later. Specifically, good baseline glycemic control was noted with the
lowest glucose levels of 89.9 mg/dL +/- 10.9 SD and lowest HbA1c levels of 5.4 +/-5.4%. The
highest glucose was 87.6 mg/dL +/- 11.4 SD three months following radiation therapy. Minimal
GV was noted at all follow up assessments. The highest GV was one year following radiation
therapy with a glucose of 82.5 mg/dL +/- 14.4 SD.
Discussion
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The purpose of this integrative review of studies in patients with GI cancers was to
investigate the presence and methods of reporting glycemic variability (GV) during and following
treatment. We conclude that GV was present in a variety of GI tumor types following cancer
treatment. Results varied across studies regarding all glycemic measures (e.g., glucose, HbA1c,
and GV). Some studies showed improvement in single glucose or HbA1c measures, however
overall GV remained notable (An et al., 2013; Choi et al., 2017; Pannala et al., 2008; Shen et al.,
2015). There was a great amount of heterogeneity in methods related to timing of testing and
reporting GV measurements among the 19 studies included in this review. Additional research
focused on GV as a measure of glycemic control is needed to advance our knowledge and
understanding and increase awareness of GV among clinicians.
GV and hyperglycemia were present across the studies. There is a growing interest of
malglycemia, a term used to describe hyperglycemia, hypoglycemia, and GV, in patients with
cancer. For example, recent literature reported that an increased rate of T2D and impaired
fasting glucose are common findings in patients with pancreatic cancer (Andersen et al., 2017).
Our findings of hyperglycemia and GV in patients with pancreatic cancer are consistent with the
published literature (Nakamori et al., 1999; Pannala et al., 2008; Shi et al., 2017; Sohn et al.,
2018). In our review, GV was noted up to one year following cancer treatment despite
improvements in mean glucose or HbA1c in patients with pancreatic or gastric cancer. The
highest reported GV occurred in patients with pancreatic cancer three months following surgery
(Shi et al., 2017). While Shi et al. (2017) did not evaluate associations of GV with outcomes,
following surgery, a HbA1c greater than 7% was associated with decreased survival compared to
those patients with a HbA1c less than 7% following surgery. In alignment, while a different
population, patients with hematologic malignancies who received allogeneic hematopoietic cell
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transplantations with hyperglycemia and/or GV with SDs of > 29 mg/dL had a progressively
increased risk for non-relapse mortality (Hammer et al., 2009).
Regarding glycemic control, patients with pancreatic cancer who underwent surgery had
improved glycemic control and, in some patients, resulted in the resolution of T2D (Pannala et
al., 2008; Sohn et al., 2018). Improved glycemic control following surgery also was observed in
patients with gastric cancer. Only two studies reported GV in patients who were treated with
chemoradiation. Both studies included patients with gastric cancer without T2D and neither
found changes from baseline HbA1c, glucose, and GV to one year following therapy (Gemici et
al., 2013; Kandaz M. et al., 2017). In the four studies that evaluated oral glucose tolerance tests
some patients improved to a normal glucose tolerance, while others changed from a normal to
an abnormal glucose tolerance following surgery (Miholic et al., 1993; Nakamori et al., 1999;
Sagor et al., 1981; Yoshikawa et al., 2012). The findings from this integrative review of GV in
patients with GI cancer support that hyperglycemia and GV are prevalent in patients with GI
cancer and are worthy of further investigation.
Differences within demographic information, types of GI cancer, and comorbid
conditions may explain inconsistencies among results. For example, the majority of the studies
in our review did not include details of the comorbidities or the duration of T2D prior to cancer
treatment. However, two studies support that the duration of T2D prior to the onset of cancer
may be an important contributing factor to impaired glycemic control following surgery. The
large studies by Pannala et al. (2008) and Sohn et al. (2018) of patients with pancreatic and nonpancreatic cancers both suggested that patients with new onset T2D may have improved
glycemic control following cancer surgery compared to those with long-standing T2D. These
findings support further investigation of duration of T2D prior to the diagnosis of cancer on
glycemic control during and following cancer treatment.
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Regarding methods, there was considerable heterogeneity related to timing of glucose
testing among the 19 studies included in this review. The majority of studies reported glucose
levels within the perioperative time period and evaluated glucose regulation following gastric
cancer surgery. Most studies were conducted in Asia where rates of gastric cancer are higher
than in other parts of the world (Bray et al., 2018). Differences among treatment follow-up
times across geographic regions and cultures may have contributed to variances in the findings.
Studies differed by cancer type, but most studies included patients with gastric or pancreatic
cancer. Therefore, these results cannot be generalized to the broader population of patients
with GI cancer.
The most commonly reported methods of measuring GV across the studies were fasting
glucose with SD, SEM, IQR, or analysis of differences between HbA1c measures. No studies
reported %CV. The value of 36%CV was adopted recently as the value that separates stable and
unstable glycemic control in patients with T2D who use a continuous glucose monitor (Danne et
al., 2017; Monnier et al., 2018). However, the majority of the studies were conducted prior to
the commercialization of continuous glucose monitors.
The increasing use of continuous glucose monitoring supports the inclusion of %CV as a
method to monitor glycemic control. The %CV threshold that will separate stable and unstable
glycemic control in patients with and without T2D and with or without continuous glucose
monitoring is yet to be determined. Foundational work by Hirsch (2005) suggested that GV of SD
X 3 < mean glucose would be “ideal”. Based on the framework, other methods of assessing GV
in various populations have been undergoing development and testing to align with thresholds
that are most often associated with adverse events and complications in patients (Hirsch, 2005).
However, to date no specific cut-points have been identified and guidelines are yet to be
developed. Additional research focused on GV as a measure of glycemic control is needed to
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increase our understanding of GV in patients with GI cancer. HbA1c is not a reliable
measurement of glycemic control in patients receiving cancer treatment and GV provides an
alternative method of glycemic control.
Strengths and Limitations
To our knowledge, this integrative review was the first to identify and describe the
presence and methods of reporting GV in patients with GI cancers. Notably, the composite of
the 19 studies included a large sample of 1526 patients with GI cancer. The moderate strength
quality of all articles supports the finding that research in this area is in its nascence (Conn &
Rantz, 2003). While there were several strengths of this review, limitations were noted.
A significant limitation was that GV was not a primary or secondary aim of any study and
associations between GV and other variables were not investigated. Given the heterogeneity
between types of GI cancers, study measures (e.g., glucose, HbA1c, SD, SEM, and IQR), timing of
assessments, and available variables across studies, the synthesis of findings were limited. In
addition, the lack of a clear, universally accepted definition of GV at a clinically relevant level
prevented the ability to conclude what an acceptable level of GV should be. The only analytical
method with a threshold that separates stable and unstable glycemic control in patients with
T2D is %CV and this method of assessment was not included in any of the studies. While SEM
was reported in five studies and is often used interchangeably with SD, it is best used to
construct confidence intervals and not to report sample variability (Barde & Barde, 2012).
More than one-half of the studies in this review included patients with a diagnosis of
T2D but less than one-half of these studies reported on the medical management of T2D. Most
of the studies were retrospective or small prospective case-control studies. Only six studies
included patients who received chemotherapy and/or radiation therapy and only one study
evaluated doses of chemotherapy and radiation. Glucose and GV measurements also were
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lacking in the weeks and months that patients received chemotherapy. The patient’s ability to
complete treatment or whether glucocorticoids, a known inducer of hyperglycemia, were
administered was not reported in any of the studies. While the limitations of this review are
notable, this review highlighted the high prevalence of GV among patients with GI cancers.
Inclusion of GV measures and assessments in future studies of patients with cancer can
contribute to advancing the science in regard to glycemic control.
Implications
Nurse scientists have a unique opportunity to design research to advance understanding of
why patients with cancer and T2D have a higher risk of morbidity and mortality than those
without T2D. To our knowledge, there are no published studies of patients with GI cancer that
included GV as a primary outcome variable. Nursing research can add to the limited
understanding of GV in patients with cancer by reporting GV, specifically %CV, and using
sequential glucose values.
Consistent with reports in the literature, a total of 27.6% of the patients represented across
10 studies were reported to have T2D at baseline. The alarming increase in T2D in the general
population supports an urgent call to action. This review can stimulate clinical discussions on
methods to use to monitor T2D during cancer treatment. Education on the role of measuring
GV can add to clinician understanding of GV in patients with cancer. Studies that report GV in
patients with cancer will inform future research designed to test interventions to mitigate risks
of complications in patients with cancer who have T2D and experience GV.
Conclusion
Patients with GI cancer experience GV during and up to one year following cancer
treatment. The inconsistency and variation in methods used to report glucose and HbA1c have
limited the ability to identify and compare associations with GV in patients with cancer. Data
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support that the evaluation of glycemic control with an acute real time measurement (e.g.,
glucose), instead of average glycemic status (e.g., HbA1c), may provide a more accurate
assessment in patients with cancer. Oncology nurses and advanced practice providers are an
integral part of the multidisciplinary cancer team and can stimulate discussion and contribute to
assessment and monitoring of GV. Future research that investigates glycemic control in patients
with cancer, with and without T2D, will contribute to better understanding of the risks
associated with GV. Progress can be made when studies that report glucose and HbA1c in
patients with cancer also include measurements of GV with %CV or SD. Long-term studies are
needed that evaluate associations between GV and cancer outcomes.
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Table 1
Quality Assessment of Studies (Based on rating of 1-5 with 5 being highest quality)

Reference

Randomization

(An et al., 2013)

N

Statistical
Analyses
Appropriate
Y

(Cao et al., 2011)

Y

(Choi et al., 2017)

Limitation

Quality Rating

Single institution, small sample, cancer stage not
included

3

Y

Single institution, small sample, non-blinded, short
follow up to postoperative day 5, cancer stage not
included

5

Y

Y

Single institution, small sample, underpowered, diet
habits and nutrition education not studied, diabetes
duration stratified > or < 5 years instead of # of yrs

5

(Gemici et al.,
2013)

N

Y

Single institution, small sample, nonrandomized, mixed
stages but all early stage eligible for adjuvant treatment

3

(Kandaz M. et al.,
2017)

N

Y

Single institution, small sample, nonrandomized, mixed
stages but all early stage eligible for adjuvant treatment

3

(Long et al., 1990)

N

Y

Single institution, small sample, nonrandomized, short
follow up, mixed stages including patients with
metastatic disease

2

(Lundholm et al.,
2010)

Y

Y

Single institution, small sample, short follow up, cancer
stage not included

5

(Miholic et al.,
1993)

N

Y

Single institution, small sample, nonrandomized, cancer
stage not included

2
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Table 1 Continued
Quality Assessment of Studies (Based on rating of 1-5 with 5 being highest quality)
Reference

Randomization

Statistical
Analyses
Appropriate
Y

Nakamori et al.,
1999)

N

(Pannala et al.,
2008)

N

Y

(Sagor et al., 1981)

N

Y

(Shen et al., 2015)

N

Y

(Shi et al., 2017)

N

Y

(Sohn et al., 2018)

N

Y

(Xiao-Bo et al.,
2014)
(Yoshikawa et al.,
2012)

Y

Y

N

Y

(Zhang et al., 2013)

N

Y

(Zhao et al., 2014)

Y

(Zhu et al., 2013)
Note. Y = yes, N = no

Y

Limitation

Quality Rating

Single institution, small sample, nonrandomized,
glucose levels not stated but only reported in graph

2
3

Y

Single institution, small sample, nonrandomized,
retrospective, cancer stage not included, timing of
testing varied. Self-reported medical history
Single institution, small sample, nonrandomized,
retrospective, wide range of timing of test postop,
glucose levels only estimates on graph
Single institution, small sample, nonrandomized,
retrospective, short follow up
Single institution, small sample, nonrandomized,
retrospective, cancer stage not included
Single institution, small sample, nonrandomized, short
follow up, cancer stage not included
Single institution, short follow up, cancer stage not
included, no preoperative assessment
Single institution, small sample size, nonrandomized,
retrospective, attrition/missing data, timing of testing
not known, varied GI cancers, cancer stage not
included.
Single institution, small sample, nonrandomized, cancer
stage not included, mismatched groups
Single institution, small sample, short follow up

Y

Single institution, small sample size, short follow up

4

2

3
3
4
5
1

3
4
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Table 2
Study Characteristics
Reference, Country

Design

(An et al., 2013),
South Korea

Cancer
Type

Total
Sample
Size

Age
(yrs)

DM
Affect

Treatment

Chemotherapy
Allowed

Measurement
(mean +/- SD if
not otherwise
specified)
FBG
HbA1c

Prospective data Gastric
analysis

64

62.7

Y

Surgery

N

(Cao et al., 2011),
China
(Choi et al., 2017),
South Korea

Randomized
trial, unblinded
Randomized
trial

Gastric

179

58.8

Y

Insulin

N

FBG

Gastric

40

62.6

Y

Surgery

Y

(Gemici et al., 2013),
Turkey

Gastric

53

56.3

Y

Chemo/XRT

Y

(Kandaz M. et al., 2017),
Turkey

Prospective
descriptive
study,
longitudinal
Prospective,
investigational

FBG
HbA1
PP2
FBG
HbA1c

Gastric

75

55

N

Chemo/XRT

Y

FBG
HbA1c

(Long et al., 1990),
United States

Prospective,
investigational

15

69

N

Surgery & TPN

N

FBG

(Lundholm et al., 2010),
Sweden

Randomized,
double blinded

Colon
and
rectal
Varied GI

31

74.5

N

Ghrelin

N

FBG
(Mean, SEM)

(Miholic et al., 1993)
Austria

Prospective case
control

Esophageal

24

57

N

Surgery

-

BG
PPG
(Mean, SEM)
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Table 2 Continued
Study Characteristics
Reference, Country

Design

(Nakamori et al., 1999),
Japan

Pancreas

64

60.5

Y

Surgery

-

Pancreas

1445

66

Y

Surgery

Y

FBG

Gastric

21

59.5

N

Surgery

-

FBG
(Mean, SEM)

(Shen et al., 2015),
China

Prospective case
control,
matched groups
Prospective data
analysis, registry
data,
longitudinal
Prospective,
case control,
convenience
sample,
observational
Retrospective
study

Gastric

46

60.1

Y

Surgery

-

FBG

(Shi et al., 2017),
China

Retrospective
cohort study

Pancreas

52

60.3

Y

Surgery

-

FBG
HbA1c

(Sohn et al., 2018),
South Korea

Prospective
cohort study

Pancreas
& varied
GI

104

64.8

Y

Surgery

Y

FBG
HbA1c
(Mean,
IQR)

(Pannala et al., 2008),
United States

(Sagor et al., 1981),
England

Cancer
Type

Total
Sample
Size

Age
(yrs)

DM
Affect

Treatment

Chemotherapy
Allowed

Measurement
(mean +/- SD if
not otherwise
specified)
FBG

53

Table 2 Continued
Study Characteristics
Reference, Country

Design

Cancer
Type

Total
Sample
Size

Age
(yrs)

DM
Affect

Treatment

Chemotherapy
Allowed

Measurement
(mean +/- SD if
not otherwise
specified)
FBG

(Xiao-Bo et al., 2014),
China

Randomized single
center clinical trial

Esophageal

120

64.1

N

Surgery and
Nutrition

-

(Yoshikawa et al., 2012),
Japan

Prospective,
observational

Varied
GI

36

62.7

Y

Surgery

-

FBG
HbA1c

FBG
HbA1c
(Mean, SEM)
FBG
(Mean, IQR)

(Zhang et al., 2013),
China

Prospective
observational

Gastric

21

55.8

Y

Surgery

N

(Zhao et al., 2014),
China

Randomized
single center
clinical trial

Esophageal

68

56.5

N

Surgery

Y*

(Zhu et al., 2013),
China

Randomized
single center
clinical trial

Gastric

60

60.4

N

Analgesia
type

N

FBG (Mean,
IQR)

Note. DM = diabetes mellitus. Y = yes, N = no. BG = blood glucose (non-fasting). FBG = fasting blood glucose. HbA1c = hemoglobin A1c. PP2 =
postprandial 2 hour glucose. chemo/XRT = chemoradiation therapy. TPN = total parenteral nutrition. SD = standard deviation. SEM = standard
error of mean. IQR = interquartile range. OGTT = oral glucose tolerance test.  not reported. *Neoadjuvant chemotherapy allowed
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Table 3
Timing of testing and mean glucose measurements at baseline and post-baseline, ¶Results converted from mmol/l to mg/dL • BG mg/dL,

HbA1c %

Reference

Groups

Time

Baseline

(An et al.,
2013)

a

STG B1,
b
STG BII,
c
TG

Before
surgery & 3,
6, & 12 mo
after surgery

(Cao et al.,
2011) ¶

d

IG,eCG

Before
surgery &
POD 1,3, 5

d•

(Choi et al.,
2017)

f

RY, gBI

Before
surgery, 3,
6, 9, & 12
months
after
surgery

f•

POD
Day 4-8

125 +/- 30.3, 
6.8-0.6%; b•
136+/-56.6, 
6.9 +/-1.4; c•
114.3 +/-22.2, 
6.5-0.7%

a•

a•

147.3 +/44.1,  7.2-1.1;
b•
155.7+/-40, b
7.3+/-1.3; c•
145.9 +/-37.5, 
7.1 +/-0.8
122.4 +/- 10.8,

7.5 +/-0.7; e•
126 +/- 12.6
mg/dL,  7.3 +/0.6
134.1 +/-40.2,

7.2 +/- 0.9; g•
136.2 +/-37.4,

7.6 +/- 1.2

1- 3 mo

6 mo
a•

122.3 +/-38.5,

7.0 - 0.7; b• 122.5
+/-31.9, 7.1+/1.3; c• 117 +/- 28,

6.5 +/- 0.5%

12 mo +
a•

114.4 +/- 21.7,
7.1- 0.9; b•
126.4 +/- 39.1,

7.1 – 1.6; c•
115.4 +/-27.3, 
6.5-0.6


POD 5: d• 99
+/- 14.4, e•
178.2 +/- 18

122.9 +/-28.8  f• 111.8. +/-20.1 
6.4 ± 0.5, g• 128.2 6.5 ± 0.6, g• 128.0
+/- 25.5, 6.9 +/- +/- 35.1, 7.1 +/0.8
0.8;
f•

130.1 ± 35.7, 
6.7 ± 0.6, g•
123.0 ± 28.7 , 
6.9 ± 0.6
f•
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Table 3 Continued
Timing of testing and mean glucose measurements at baseline and post-baseline, ¶Results converted from mmol/l to mg/dL • BG mg/dL,

HbA1c %
Reference
(Gemici et
al., 2013)

Groups
h

ChemoXR
T iControl

(Kandaz M.
et al.,
2017)

Time
Before
surgery, 3 or
6 mo after
surgery & at
1 yr
Before RT, 3
mo, 6 mo, 1
yr after RT

Baseline

•

•

89.9+/-10.9,

5.4+/-0.5

fasting, k Before
preop TPN, l surgery &
postop TPN POD 5

j•

(Lundholm
et al.,
2010) ¶

m

m•

k•

91.7 +/-6.6,
140. +/-16.4

111.6 +/5.4, n• 108 +/7.2

6 mo

87.6 +/- 11.40,

5.5-0.6
POD5: l144.6 +/12.3

12 mo +

90.6 +/-12.4, 5.5
+/- 0.5, i• 95.2 +/11.3, 5.9 +/-0.7

h•

•

•

h•

92.5 +/-12.2,

5.5 +/- 0.5, i•
95.1 +/- 22.3,

5.9 +/-0.7

J

Before
Ghrelin &
after 8 weeks
on therapy

1- 3 mo

h•

(Long et
al., 1990)

HighDose
Ghrelin,
n
Low-dose
Ghrelin

POD
Day 4-8

87.11 +/-13.22,

5.49 +/-0.6

88.5 +/- 10.5,
5.7 +/- 0.6 vs i•
90.6 +/- 18, 6.2
+/- 0.5


.

m•
n•

131.4 +/- 12.6
118.8 +/-12.6

82.45 +/-14.36,
5.7 +/- 0.3
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Table 3 Continued
Timing of testing and mean glucose measurements at baseline and post-baseline, ¶Results converted from mmol/l to mg/dL • BG mg/dL,

HbA1c %

Reference

Groups

(Miholic et
al., 1993) ¶

o

Esophagectomy
p
Control

OGTT 0-30, 0180 min post
test meal
(median 6 mo
after surgery)

(Nakamori
et al.,
1999)

q

cancer
non-DM,
r
control
non-DM,
s
cancer+D
M,
control+D
M

0,30, 60, 120,
and 180 min
OGTT 2-3 mo
after surgery;
Values are
estimates
from graph

q•

u

Before
surgery & 30676 days after
surgery

u•

(Pannala et
al., 2008)

Time

PaCDM,
v
PaCDM2yr
, wPaCDM_
long

Baseline

POD
Day 4-8
o
p
90 +/- 3.6 90
+/-3.6

95 +/-15, r•
98 +/-13, s•171
+/- 36 t• 178 +/34

175 +/-48, v•
174.2 +/-49, w•
175.5 +/-49.3

1- 3 mo

6 mo

12 mo +

OGTT: 0-30 min: o•
160.2+/-3.6, p
122.4+/-3.6; 0-180
min o • 90 +/-3.6 p•
81 +/-3.6
OGTT 0-30 q•
150+/-50, r • 150
+/-50, s • 285 +/50, t • 285 +/-50;
0-120: q • 125
+/-25, r • 113 +/25, s • 360 +/-75,
t•
400 +/-25; 0180: q • 100 +/50, r • 90 +/-25, s
•
350 +/-75, t •
350 +/-75
U•

120 +/-32, v •
110 +/-19.1, w •
145 +/-44.3

57

Table 3 Continued
Timing of testing and mean glucose measurements at baseline and post-baseline, ¶Results converted from mmol/l to mg/dL • BG mg/dL,

HbA1c %

Reference

Groups

Baseline

Fasting, OGTT
between 1-18
mo after
surgery.
Values are
estimates
from graph

X•

(Shen et al.,
2015)

Before &
within 20 days
after surgery,
day 21 to 3
mo

•

(Shi et al.,
2017)

Monthly for
12 mo, then
every 3 mo.

•

(Sagor et al.,
1981) ¶

x

Time

total
gastrectomy
, y upper
partial
gastrectomy
, z control,
minor
surgery

z•

POD
Day 4-8

1- 3 mo

6 mo

86.4, y•86.4,
81

136.8+/- 18

130 +/-60;

6.7 +/- 1.5%

12 mo +

OGTT 0-30 min: x
•
162 +/-18,
y•
158.4 +/- 10.8,
z•
126 +/-14.4; 0120 min X•171 +/18, y144 +/-18,
z•
140.4 +/-28.8
•

129.6 +/- 27

•

108 +/-45

• 167
153 +/-84 (1 mo),
149 +/- 68; 

+/-94 (3 mo); 6.76.8
+/-+/-0.8

0.8 (1 mo); 7.2 +/- 1
(3 mo)
•

142 +/- 79;  6.5
+/- 0.8
•
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Table 3 Continued
Timing of testing and mean glucose measurements at baseline and post-baseline, ¶Results converted from mmol/l to mg/dL • BG mg/dL,

HbA1c %
Reference

Groups

Time

(Sohn et al.,
2018)

aa

pancreatic
cancer,
ab
nonpancreatic
cancer

Before
surgery & 6
mo after
surgery.

(Xiao-Bo et
al., 2014) ¶

ba

POD 1
(baseline) &
POD 8.

Enteral
nutrition,
bb
TPN

(Yoshikawa
et al., 2012)

(Zhang et
al., 2013) ¶

Baseline

Before & after
surgery

ca

T2DM,
IGT, cc
NGT
cb

Baseline & 3
mo, 3 mo
values
estimates
from graph

POD
1- 3 mo
Day 4-8
aa•
116 (range
102-136);  6.6
(range 6-7.3);
ab•
98 (90-124),

5.6 (5.3-6.1)
138 +/-10.8 POD8: ba 135
(POD 1), bb•
+/-7.2 mg/ dL;
bb•
131.4 +/- 14.4
181.8 +/(POD 1)
10.8
•
98.5 +/- 17;

5.4 +/-1 (OGTT
levels not
reported)

6 mo
aa•

100 (range 82100),  6.1 (range
5.7 – 6.8); ab• 97
(range 91-107)

6.1 (range 5.76.6)

ba •

ca•

62.4 +/12.6,  7 +/-0.3;
cb•
91.8 +/-3.6,

5.9 +/-0.2; cc•
91.8 +/- 3.6,
5.5 +/-0.1

12 mo +

•

104.1 +/-23.7
(mean POD
18.5) (OGTT
levels not
reported)
ca 

6.2 +/-0.2; cb

5.5 +-0.3; cc 
5.5 +/-0.2
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Table 3 Continued
Timing of testing and mean glucose measurements at baseline and post-baseline, ¶Results converted from mmol/l to mg/dL • BG mg/dL,

HbA1c %
Reference

Groups

Time

(Zhao et al.,
2014) ¶

da

db

FTS,
Conventional
pathway

(Zhu et al.,
2013) ¶

ea

PCEA, eb
PCIA

Baseline

POD
Day 4-8

1- 3 mo

Before
surgery, POD
1, 3, 7.

da•

98.46 +/7.7 (quartile),
db•
96.6 +/10.6 (quartile)

POD 7:da•
115.9 +/- 92 ,
db•
121.9 +/18.7
(quartiles)

POD 1 & 4.

ea•

POD 4: ea•
88.2 (range
79.2-93.6),
eb•
81 (75.6 –
90)

82.8 (range
79.2-90); eb• 90
(range 75.6 –
93.6)

6 mo

12 mo +

Note. BG = blood glucose. HbA1c = hemoglobin A1c. OGTT = Oral glucose tolerance test. Min = minute. Mo = month. Yrs = years. POD =
postoperative day. TPN = total parenteral nutrition. asubtotal gasterectomy with Billroth 1 anastomosis; bsubtotal gastrectomy with Billroth
II anastomosis; ctotal gastrectomy; dintensive insulin therapy; econventional insulin therapy; fRoux-en-Y gastrectomy; ggastroduodenostomy;
h
adjuvant chemoradiation; icontrol group, no adjuvant chemoradiation; Jfasting; k preop TPN; l postop TPN; mHigh-Dose Ghrelin; nLow-dose
Ghrelin;o Esophagectomy; OGTT: oral glucose tolerance test; pcontrol; qcancer nonDM = cancer without diabetes; rcontrol, nonDM = control
without diabetes; scancer+DM = cancer with diabetes; tcontrol+DM = control with diabetes; uPancreatic cancer with diabetes; vPancreatic
cancer with diabetes 2 years or less; wPancreatic cancer with diabetes chronic > 2 yrs; xtotal gastrectomy; yupper partial gastrectomy; z
control, minor surgery; aapancreatic cancer; abnon-pancreatic cancer; baenteral nutrition following esophagectomy; bbTPN = total parenteral
nutrition following esophagectomy. caT2DM = type 2 diabetes mellitus. cbIGT = impaired glucose tolerance. cc NGT = normal glucose
tolerance. da FST = fast track surgery. db Conventional pathway. ea PCEA = patient controlled epidural analgesia. ebPCIA = patient controlled
intravenous analgesia.
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Figure 1: Prisma Diagram.
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Figure 2: Range of Glycemic Variability at Baseline to One Year Following Treatment.
Note. Results of glycemic variability reported with glucose and standard deviation in 11 studies.

62
CHAPTER 3: MANUSCRIPT #2
Glycemic Variability Within One Year Following Surgery for Stage II-III Colon Cancer

63

Glycemic Variability Within One Year Following Surgery for Stage II-III Colon Cancer

Natalie C. Mandolfo
Nursing Graduate Program, The University of Nebraska Medical Center
November 2, 2020

64
Abstract
Aim. To examine glycemic variability within one year among adult patients, with and without
Type 2 Diabetes, treated with surgery for stage II-III colon cancer.
Methods. A retrospective analysis of electronic health record data of 165 patients with stage IIIII colon cancer was conducted. Glycemic variability (i.e., standard deviation [SD] and coefficient
of variation [CV] of >2 blood glucose measures) was assessed within one month and within one
year following cancer surgery.
Results. Patients with stage II-III colon cancer with diabetes had higher glycemic variability
(p<.001) within one month (SD=2.48 mmol/L; CV = 27.4%) and within one year (SD=2.5 mmol/L;
CV=29.04%) following surgery compared to glycemic variability in patients without diabetes
within one month (SD=1.14 mmol/L; CV=17.53%) and within one year (SD=1.19 mmol/L; CV
18.6%) in patients without diabetes. Cumulative steroid dose over one year (r= -.639, p<.01) and
race (r= -.413, p<.05) had the strongest associations with SD one month following surgery in
patients with diabetes. Moderate associations were found between BMI and SD (r=. -.413,
p<.05) and CV (r= -.481, p<.01) one month following surgery in patients with diabetes.
Preoperative glucose (r=.448) was associated with one year SD in patients with diabetes (p<.01).
Weak associations between demographic/clinical characteristics and glycemic variability were
observed in patients without diabetes.
Conclusion. Patients with stage II-III colon cancer with diabetes experienced higher glycemic
variability within one month and within one year following surgery compared to those without
diabetes. Associations between glycemic variability and demographic and clinical characteristics
differed by diabetes status and measurements.
Keywords: colon cancer, diabetes, glucose, glycemic variability, surgery, treatment
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Glycemic Variability Within One Year Following Surgery for Stage II-III Colon Cancer
Diabetes and colon cancer are two non-communicable global health challenges that are
rising in incidence. One in five adults over the age of 65 years has diabetes and the number of
adults living with diabetes is expected to rise from 406 million world-wide in 2019 to 700 million
by 2045 (International Diabetes Foundation, 2019). In addition, individuals with diabetes have a
27% higher risk of developing colon cancer compared to individuals without diabetes. In 2018
>1.8 million people were diagnosed with colon cancer worldwide with an estimated increase to
2 million annually by 2040 (International Agency for Research on Cancer, 2020).
Establishing stability of glucose is important in patients receiving care in the hospital or
ambulatory setting (American Diabetes Association, 2020). Determining stable glycemic control
in patients with cancer is yet to be defined and practice guidelines for diabetes management in
patients with cancer are lacking. Hemoglobin A1c (HbA1c) is a current accepted determinant of
glycemic control among patients with diabetes; however, using HbA1c as the standard is
questionable (Garber et al., 2017; Gorst et al., 2015; Kovatchev, 2019). Limitations are notable
(Kovatchev, 2019) due to the dependency on erythrocyte stability, which can be altered by
comorbidities including cancer (Campbell et al., 2019; Fayyaz et al., 2019). Notably,
chemotherapies used to treat cancer impact hematopoiesis; therefore, HbA1c values in patients
with cancer may not be reflective of actual glycemic state.
While HbA1c reflects the mean level of blood glucose over 2-3 months (American
Diabetes Association, 2020), it fails to capture multiple episodes of hypoglycemia,
hyperglycemia, and glycemic variability (i.e., malglycemia) (Hammer et al., 2009) or dysglycemia
(perturbations in post-prandial blood glucose) (Ceriello et al., 2019). In particular, glycemic
variability reflects excursions of blood glucose and describes the frequency and rate of
fluctuations. Glycemic variability serves as a marker of instability of the metabolic system
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(Kovatchev, 2019). Glycemic control can be evaluated by measuring glycemic variability through
both short-term (within-day/between-day) and long-term (visit-to-visit) fluctuations in serial
glucose values (Ceriello et al., 2019). Glycemic variability can be reported as standard deviation
(SD) of mean glucose and/or coefficient of variation (CV) of glucose using serial glucose values
(Ceriello et al., 2019; Kovatchev, 2019; Peyser et al., 2018). There are numerous other methods
of calculating glycemic variability, including mean amplitude of glycemic excursions (MAGE) and
mean absolute glucose change (MAG). However, no universally accepted method of reporting
glycemic variability exists and there are inconsistencies in defining values for unstable glycemic
control in patients with diabetes (Kovatchev, 2019).
Guidance for measuring glycemic variability in patients with diabetes who use a
continuous glucose monitoring system (CGMS) has recently emerged (Ceriello et al., 2019;
Danne et al., 2017). A CV value of >36% has been adopted as the cut-point separating stable and
unstable glycemic control in patients with diabetes using a CGMS (Ceriello et al., 2019; Danne et
al., 2017; Kovatchev, 2019; Monnier et al., 2018). However, CGMS in clinical practice is not yet
the standard of care for patients with cancer and/or other chronic or acute illnesses (Peyser et
al., 2018). Gycemic variability measures may also be appropriate for those with increased use of
inpatient and emergency services (Carlson et al., 2017).
There are very few reports of glycemic variability in patients without diabetes and even
fewer studies of glycemic variability in patients with cancer. There are no established glycemic
variability levels that separate stable and unstable glycemic control in patients with cancer. An
SD value of >29 mg/dL (1.61 mmol/L) was considered the level at which patients had an
increased risk of adverse events in a study of 1,175 patients with hematologic cancers (diabetes
status unknown) treated with allogeneic hematopoietic cell transplant (Hammer et al., 2009).
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There is a critical gap in the literature with very few reports of glycemic variability in
patients with cancer. However, several studies have reported associations between glycemic
variability and adverse health outcomes in the general population. Studies have reported
associations between glycemic variability and vascular complications (Gorst et al., 2015),
progression of diabetic neuropathy (Cheng et al., 2014; Lai et al., 2019), end stage renal disease
(Yang et al., 2015), and cognitive decline (Yu et al., 2019). One recent study identified that
glycemic variability was associated with higher 30 day postoperative mortality (Akirov et al.,
2019). Glycemic variability has also been found to be associated with higher mortality in patients
with congestive heart failure (Gu et al., 2018), and in critically ill and hospitalized patients
(Atamna et al., 2019; Singh et al., 2018). Other studies have examined associations between age,
gender, body mass index (BMI), obesity, and race with glycemic variability; however, findings
have been inconsistent in studies of patients with and without diabetes (Echouffo-Tcheugui et
al., 2019; Gude et al., 2017; Hill et al., 2011; Kim et al., 2014; Salkind et al., 2014). Gender, race,
and socioeconomic characteristics are known to impact outcomes in patients with diabetes, but
little is known about their influence on glycemic variability (Kautzky-Willer et al., 2016; Walker
et al., 2016). Furthermore, obesity management is recommended by the American Diabetes
Association to improve glycemic control (American Diabetes Association, 2020) and associations
between obesity and glycemic variability should be explored. Few studies have investigated the
impact of these demographic and socioeconomic characteristics on glycemic variability in
patients with and without diabetes.
An integrative review that identified the presence of glycemic variability in patients with
gastrointestinal (GI) cancer found that glycemic variability has not been reported as an outcome
measure in patients with GI cancer (Mandolfo et al., 2020). However, findings did indicate that
glycemic variability was present in patients with gastric and pancreatic cancer for up to a year
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following cancer surgery, even among those with improvements in blood glucose and/or HbA1c
(Mandolfo et al., 2020). No studies were identified that evaluated glycemic variability in groups
composed of only patients with colon cancer. Only one study including a group of 9 patients
with a variety of stages of colon and rectal cancer, without diabetes, reported glucose and
standard error of the mean (SEM) over five days following surgery. All patients were treated
with total parental nutrition before and after surgery, findings suggested that glucose and SEM
were similar while on total parental nutrition preoperatively and 5 days following surgery (Long
et al., 1990). A gap in the literature was identified; no studies investigated glycemic variability
using a recognized method such as SD or CV in a homogenous group of patients with stage II-III
colon cancer following surgery.
There are a limited number of reports of the associations between glycemic variability,
cancer development, and cancer related outcomes. In patients with hematologic cancer, high
glycemic variability was associated with twice the risk of infection and a 14.5-fold higher risk of
non-relapse mortality when comparing the upper quartile to the first quartile (Hammer et al.,
2009). Higher glycemic variability was also found to be associated with lower remission rates
and reduced overall survival (age >60 years old) in patients with acute myelogenous leukemia
(Kuhlman et al., 2019). Recent studies identified that glycemic variability in patients without
cancer was also associated with a future diagnosis of cancer supporting the hypothesis that
glycemic variability is associated with tumorigenesis (Kobayashi et al., 2020; Saito et al., 2019).
Little is known about the impact that glycemic variability has on patients with cancer.
Therefore, the purpose of this retrospective study was to examine glycemic variability within
one year among adult patients, with and without Type 2 Diabetes, treated with surgery for stage
II-III colon cancer. The specific aims in a sample of 165 patients, in groups with and without Type
2 Diabetes, within one month and within one year following surgery were to: 1) determine
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levels of glycemic variability between groups and 2) describe associations between glycemic
variability and patient demographic and clinical characteristics.
Materials and methods
Research Design
This descriptive, correlational, longitudinal, medical record study explored glycemic
variability during the first month and within one year following surgery in patients with stage IIIII colon cancer.
Study Population
The study was a retrospective analysis of electronic health record (EHR) data of patients
with stage II-III colon cancer from a single, 809-bed university affiliated tertiary medical center
and National Cancer Institute (NCI) designated cancer center. Patients with stage II-III colon
cancer, as per the American Joint Committee on Cancer (AJCC) staging system, were identified
from the cancer center registry. The registry collects data on all patients diagnosed and/or
treated for cancer at the cancer center and affiliated hospital.
Inclusion criteria were patients age 19 years or older; a diagnosis of stage II-III colon
cancer between August 1, 2012 and November 30, 2018; and confirmed treatment with surgery
with or without chemotherapy. If chemotherapy was administered it must have included a 5Fluorouracil or capecitabine based regimen representing the standard of care for adjuvant
treatment of colon cancer (National Comprehensive Cancer Network, 2020). Patients were
included if they had two or more blood glucose values available within one year of surgery.
Patients with Type 1 Diabetes Mellitus were excluded.
Procedures
The health system uses the EPIC EHR product (Epic Corporation, Verona, WI). The list of
EHR codes for the variables of interest were identified with assistance of the department of
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clinical and translational research. Upon IRB approval, an EHR query of data from all patients
age 19 years or older, diagnosed with stage II-III colon cancer between August 1, 2012 and
November 30, 2018 and who were treated with surgery and/or chemotherapy was conducted.
Data are shown in Table 1 for all variables extracted from the EHR, including
demographic and clinical characteristics, diabetes status at time of surgery, glucose values,
cancer treatment information, and blood culture results. Data extraction was completed by staff
from the department of clinical and translational research. Of 213 cases, 165 met our inclusion
criteria.
The main outcome variable was glycemic variability within one month and one year
following surgery for colon cancer. Glycemic variability was determined by the SD (mmol/L) and
CV. CV was determined by using the formula of %: (SD÷Mean)x100 (Ceriello et al., 2019; Danne
et al., 2017). Diabetes status prior to surgery was determined by identification of ICD-CM-10
codes of E08-E13 in the EHR. A search of the EHR to confirm a diagnosis of diabetes was
performed on all patients who did not have documentation of diabetes and had either 1) a
preoperative glucose value > 7.77 mmol/L, the value representing hyperglycemia in hospitalized
patients (American Diabetes Association, 2020) or 2) oral diabetes therapy and/or insulin
included in their inpatient or outpatient medication list. The glucose values were assumed to be
random, non-fasting assessments. All blood culture results that were positive for infection were
counted. Household income was not available in the EHR, therefore zip codes were used to
retrieve median household income from 2018 US Census Bureau data (US Census Bureau,
2018). EHRs were individually searched to capture missing data. Data variables were recoded
and cleaned prior to the analyses.
Statistical Analysis
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Data were analyzed using SPSS 26 (IBM Corporation, Armonk, NY, USA). Missing data
were counted as null values. Within and between group analyses were conducted on the sample
of 165 patients with and without diabetes. Continuous variables are presented by medians
(interquartile range; IQR) and categorical variables are presented by (N, %). The KolmogorovSmirnov test was used to assess normality and the Mann-Whitney U test was used to compare
continuous variables. The chi-squared (χ2) or Fisher’s exact test was used to compare categorical
characteristics between groups. Results are reported as numbers and percentages. Correlation
coefficients were determined using Spearman’s correlation analysis. Statistical significance was
set at P <.05.
Results
Baseline Demographic and Clinical Characteristics
Demographic and clinical characteristics are detailed in Table 2. In brief, 23.6% of the
sample had a documented diagnosis of diabetes prior to surgery. The mean age was 71.5 +/-9
years in patients with diabetes compared to the mean age of 63.7 +/-14.94 years in patients
without diabetes (p=.002). There was a total of 6,509 glucose values across the sample . There
were two-to-three times the number of glucose measures for patients with diabetes compared
to patients without diabetes. Differences in employment (p=.004) and insurance status (p=.021)
were reported with a higher number of patients with diabetes being retired (76.9%, n=30) and
enrolled in a federal insurance plan (69.2%, n=27) compared to patients without diabetes (50%,
n=63; 46.8%, n=59).
Compared to patients without diabetes, preoperative blood glucose was higher in
patients with diabetes (11.17 mmol/L vs 5.28 mmol/L) (p<.001) . Among patients with diabetes,
35.9% used insulin and 41% used oral antidiabetic therapy, including metformin (43.8%).
Patients with diabetes received a lower cumulative steroid dose (112 mg) over one year
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following surgery compared to patients without diabetes (1551 mg) (p=.044). The majority of
patients with diabetes were diagnosed with stage III colon cancer (61.5%, n=24) (p=.108).
Almost 31% of patients with diabetes and 36.2% of patients without diabetes received
chemotherapy. No other differences were found between groups of patients with and without
diabetes.
Glycemic Variability in Patients With Diabetes vs Those Without Diabetes
Mean blood glucose, SD, and CV in patients with and without diabetes are shown in
Table 4. Mean blood glucose, SD, and CV were significantly higher in patients with diabetes one
month following surgery and within one year following surgery compared to those without
diabetes (p<0.001). In patients with diabetes, the one month SD was 2.48 mmol/L (1.69-2.98)
and the one year SD was 2.5 mmol/L (1.81-3.29) compared to the one month SD of 1.14 mmol/L
(.79-1.56) and one year SD of 1.19 mmol/L (.86-1.6) in patients without diabetes (p<.001).
Similarly, one month CV of 27.4% (20.11-31.04) and one year CV of 29.04% (24.63-33.34) were
significantly higher in patients with diabetes compared to those without diabetes CV of 17.53%
(12.37-22.68) and CV of 18.6% (13.98-22.68) (p<.001), respectively.
Associations Between Glycemic Variability and Demographic and Clinical Characteristics
Spearman’s correlation coefficients corresponding to the associations between glycemic
variability and demographic and clinical characteristics in patients with diabetes are shown in
Table 5 and without diabetes in Table 6.
Associations in Patients With Diabetes
In patients with diabetes, higher one month SD was associated with Caucasian race (r= .452, p<.01), a lower baseline BMI (r= -.413, p<.05), lower cumulative steroid dose over one year
after surgery (r= -.639, p<.01), and taking insulin at the time of surgery (r=.335, p<.05). Higher
one month CV was also associated with a lower baseline BMI (r= -.481, p<.01). Higher one year
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SD was associated with being male (r=.360,p<.05), married (r= -.342, p<.05), higher preoperative
glucose (r=.448, p<.01), preoperative glucose of >7.77 mmol/L (r=.413, p<.01), and insulin use
one year following surgery (r=.375, p<.05).
Associations in Patients Without Diabetes
In patients without diabetes, higher one month SD was associated with older age
(r=.227, p<.05), having federal/government insurance status (r= -.197, p<.05), and higher
number of antibiotics prescribed over one month following surgery (r=.216, p<.05). Higher one
month CV was also associated with developing metastatic disease within one year of surgery
(r=.197, p<.05) and a higher number of antibiotics prescribed over one month following surgery
(r=.194, p<.05). Higher one year SD was associated with older age (r=.206, p<.05), having
federal/government insurance (-.186, p<.05), not receiving chemotherapy (r= -.177, p<.05), and
higher number of antibiotics prescribed over one year following surgery (r=.176, p<.05). One
year CV was also associated with having federal/government insurance (r= -.185, p<.05) and
higher number of prescribed antibiotics over one year following surgery (r=.184, p<.05).
Cumulative dose of steroids was not associated with glycemic variability within one month or
within one year following surgery. Table 6 details glycemic variability across demographic or
clinical characteristics.
Discussion
To our knowledge, this is the first report of glycemic variability following surgery in
patients diagnosed with stage II-III colon cancer. Glycemic variability has not been reported as
an outcome measure in patients with GI cancer and represents a critical literature gap. The
majority of published studies have evaluated glucose control in relation to gastric and pancreatic
cancer surgery, reported mean glucoses and SDs, and generally included patients with various
types and stages of cancer. Glycemic variability, reported as CV in patients following a diagnosis
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of GI cancer, is lacking in the literature (Mandolfo et al., 2020). This study is unique in that it
provides the first report of long-term glycemic variability, measured by both SD and CV, as an
outcome following surgery for stage II-III colon cancer. Glycemic variability, a suggested marker
of optimal glycemic control in patients with diabetes, provides an alternate method to HbA1c in
assessing glycemic control in patients treated with surgery and chemotherapy for GI cancer
(Kovatchev, 2019).
Glycemic Variability in Patients With Diabetes vs Those Without Diabetes
Our first important finding was that patients with diabetes experienced higher glycemic
variability within one month and one year following surgery compared to patients without
diabetes. Patients with diabetes have consistently been found to have higher glycemic variability
(Gude et al., 2017; Mandolfo et al., 2020; Suh & Kim, 2015; Xia et al., 2017) and wider ranges of
glycemic variability (Mandolfo et al., 2020) compared to those without diabetes. Glycemic
variability in patients with diabetes measured by one month SD and one year SD exceeded the
previously reported high SD cut-point value reported by Hammer et al. (2009) of >29 mg/dL
(>1.61 mmol/L) in patients undergoing allogeneic hematopoietic cell transplant for hematologic
cancers. A value that defines high CV in patients with cancer has not been reported. Patients
with diabetes in our study did not experience glycemic variability that exceeded 36% CV, the
value suggested to reflect unstable glycemic control in patients with diabetes who use a CGMS
(Monnier et al., 2017).
Associations Between Glycemic Variability and Demographic and Clinical Characteristics
The second important finding of our study was that we identified associations between
higher glycemic variability and demographic and clinical characteristics in groups with and
without diabetes. These findings provide the beginning knowledge base about such associations
where little is known. We observed that the variables associated with higher glycemic variability
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differed within one month and one year and also by type of measurement method (SD or CV).
The literature also identified inconsistent associations between variables and different methods
of measuring glycemic variability (Akirov et al., 2019; Figueira et al., 2019; Gude et al., 2017).
Our results identified that older age was weakly associated with higher SD within one
month and within one year in patients without diabetes; consistent with findings that glycemic
variability increases with age (Gude et al., 2017). Older age and having federal insurance were
the only demographic characteristics associated with glycemic variability in patients without
diabetes. In the group with diabetes, glycemic variability was not associated with age or
insurance status. A lower baseline BMI was moderately associated with higher one month SD
and CV in patients with diabetes which is consistent with negative associations between BMI
and higher glycemic variability reported in patients with (Wang et al., 2017) and without
diabetes (Gude et al., 2017).
A moderate association was found with race, suggesting that Caucasian patients with
diabetes had higher one year SD than non-Caucasian patients. This result should be interpreted
with caution given our sample consisted mostly of Caucasian patients. Inconsistent reports of
associations between race and higher glycemic variability have been published (EchouffoTcheugui et al., 2019; Hill et al., 2011; Kim et al., 2014). Very little is known about associations
between gender and glycemic variability. We identified that males with diabetes had higher one
year SD than females, other studies have reported no associations between gender and
glycemic variability (Hashimoto et al., 2020; Timmons et al., 2017). In patients with diabetes, we
also noted a moderate association between higher one year SD and being married. The
association between race, gender, and marital status and glycemic variability following colon
cancer surgery should be further investigated in larger studies.
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Clinical characteristics associated with higher glycemic variability in patients with
diabetes included diabetes status, high preoperative glucose, insulin use, and lower cumulative
steroid dose. In patients without diabetes, the two clinical characteristics found to be associated
with glycemic variability were the number of chemotherapy cycles and development of
metastatic disease within one year of surgery.
In our study 35.9% of patients with diabetes were taking insulin at the time of surgery
and this was slightly higher than the expected 30% (Selvin et al., 2016). Use of insulin was
associated with higher one month and one year SD. This finding was not surprising as patients
are prescribed insulin for the immediate glucose lowering effect. Future studies in patients with
cancer and diabetes should investigate the associations between diabetes medication,
medication adherence, and glycemic variability as these are important factors in establishing
glycemic control.
In patients without diabetes we found a weak association between receiving
chemotherapy and lower one year SD. Patients who were fit enough to receive chemotherapy
may have favorable clinical characteristics that contribute to lower glycemic variability. In fact,
we know from the literature that higher glycemic variability is associated with higher risk of
mortality and longer hospital stays (Akirov et al., 2019; Hammer et al., 2009; Mendez et al.,
2013). This study did not evaluate associations between glycemic variability, hospital length of
stay, or postoperative mortality, all warrant further investigation.
In addition, steroids are known to induce hyperglycemia and are used frequently in
premedication regimens and to treat adverse events in patients who receive chemotherapy. In
patients with diabetes, we found that a higher cumulative steroid dose over one year following
surgery was strongly associated with lower one month SD. We believe that patients with
diabetes and higher glycemic variability within one month following surgery may have clinical
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characteristics, such as hyperglycemia, that contribute to the clinical decision to avoid or
minimize steroid use.
Prior studies have reported associations between higher glycemic variability and cancer
development in patients with diabetes (Saito et al., 2019) and without diabetes (Kobayashi et
al., 2020). The study of glycemic variability and tumorigenesis is just beginning to emerge but
the associations between hyperglycemia, cancer development, and cancer progression have
been described extensively (Giovannucci et al., 2010; Hammer et al., 2019). To best understand
the pathophysiology of glycemic variability in patients with cancer, future studies should include
oxidative stress, tumorigenesis, and the tumor microenvironment.
There is limited evidence of associations between glycemic variability and increased risk
for infections in a cancer population (Hammer et al., 2009). We aimed to examine the
association between glycemic variability and positive blood cultures but very few patients had
positive blood cultures and we did not find any associations between positive blood cultures and
higher glycemic variability. While a higher number of antibiotics prescribed within one month
and over one year following surgery were both weakly associated with higher one month and
one year SD in patients without diabetes, we do not know if the prescriptions were for
prophylactic or treatment use. Future studies are needed to investigate the association between
infection and higher glycemic variability in patients with cancer to inform interventions that can
target modifiable factors for improved outcomes.
Strengths and Limitations
The use of EHR provided an opportunity to collect retrospective information on patients
in an efficient and economic manner while allowing us to follow patients’ trajectories
throughout adjuvant chemotherapy and within one year following colon cancer surgery (Casey
et al., 2016). The ability to extract 6,509 glucose values over one year in a homogenous group of
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165 patients diagnosed with stage II- III colon cancer was a strength. Our study was limited as
data were extracted from a single institution and challenges of EHR research include concerns of
accuracy of data entry. Glucose levels were automatically imputed into the EHR which mitigates
the risk of error.
Although we conducted a rigorous search of the EHR to find missing data, we did
encounter challenges. The dataset was limited to the number of patients who met the inclusion
criteria of having a diagnosis of stage II-III colon cancer. The decision was made a priori to
include the entire sample of patients, rather than matched groups, to gain insights on the
broader group. Medical history and medication lists may be reliant on patient report and
patients who may have had undiagnosed/unreported diabetes or pre-diabetes may have been
included in the non-diabetes group. In addition, some patients may have received
chemotherapy at another institution without having this data reported in the searched dataset.
Confounding factors, such as timing of meals in relation to the glucose measurement
and comorbidities, were not taken into consideration due to limitations in the EHR. Current
procedures for coding in the EHR do not allow for capturing the diagnosis dates for infections,
therefore we were only able to include laboratory results of blood stream infections as these
were automatically imputed into the EHR. In addition, the large variability among the number of
blood glucose measures per patient greatly limits the ability to accurately capture glycemic
variability. Conducting a study with multiple uniform glucose measures is essential. Our study
was not designed to identify associations between glycemic variability and cancer survival,
future studies should include survival data for five following the cancer diagnosis. In addition, a
larger study, using matched groups would allow for multiple regression analyses, identification
of confounding variables, and determination of changes in glycemic variability over time.
Conclusions
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Our study, as expected, showed higher glycemic variability within one month and within
one year following surgery for stage II-III colon cancer in patients with diabetes. Understanding
the amplitude of glucose fluctuations is of great importance for management of patients with
cancer and diabetes. Glycemic variability may serve as a marker of optimal glucose control in a
setting where HbA1c has many limitations. Additional studies in patients with cancer, with and
without diabetes, are needed to further investigate associations between higher glycemic
variability, demographic characteristics, clinical characteristics, infection, symptoms, and cancer
related outcomes including recurrence and overall survival.
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Table 1
Variable Descriptions
Variable

Description and Measurement

Demographic
Characteristics

Aim
2

Age; BMI (kg/m2); Gender; Race; Geographic; Marital status;
Employment; Insurance; Socioeconomic
Clinical
Characteristics

Diabetes

Glucose Values

Glycemic
Variability (GV)

Cancer Treatment

2
Cancer stage; Metastatic disease within one year of surgerya ;
Prescription diabetes therapyb; Cumulative steroid doseb;
Antibiotic useb; Blood culturesc
Identified from the diagnosis code (ICD-CM-10) of E08-E13 from
the EHR problem list or diagnosis noted in EHR documents. A
preoperative glucose >7.77 mmol/Ld or if patients were taking
diabetes therapy at the time of surgery prompted a search of
surgery notes and anesthesia records to confirm diagnosis
Blood Glucose Values Tested With Beckman Coulter AU5800 or
Point of Care Tests: Glucose values from the EHR were assumed to
be non-fasting
SPSS Computation of standard deviation (SD) and coefficient of
variation (CV): GV measurement was reported as SD from the
mean and of %: (SD÷Mean)x100 (Danne et al., 2017; Monnier et
al., 2017). SDs (mmol/L) and CVs (%) were evaluated as continuous
variables. GV was calculated using all available blood glucose
values within 30 days following surgery (one month SD and CV)
and within 15 months from the time of surgery (one year SD and
CV) in all patients and computed as SD from the mean and CV of
glucose (Monnier et al., 2017).

1,2

1,2

1,2

2
Colon cancer surgery
Adjuvant chemotherapy: name, dose, date of administration,
number of chemotherapy cycles received
Radiation therapy
Note. BMI = body mass index. aIdentified by search of electronic health record (EHR). b Includes
calculation of sum. c To broadly capture the occurrence of infections, we included documented
positive blood cultures. dA preoperative glucose of >7.77 mmol/L represents hyperglycemia in
hospitalized patients (American Diabetes Association, 2020).
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Table 2
Baseline Demographic Characteristics in Patients With and Without Diabetes (N=165)
With diabetes
n=39 (%) [IQR]
71.5 +/-9.4
30.00 [25.86-35.89]
19 (48.7)

Without diabetes n=126
(%) [IQR]
63.7 +/-14.94
28.19 [24.51-33.69]
64 (50.8)

Pa
value
.002
.232
.821
.361

Age in years *mean
Baseline BMI (kg/m2)
Gender (male)
Race
Caucasian
33 (84.6)
113 (89.6)
Non-Caucasian
6 (15.4)
13 (10.4)
African American
2 (5.1)
9 (7)
Asian
0
3 (2.4)
Other
4 (10.2)
1 (.8)
Geographic region
.376
Midwest
37 (94.8)
125 (98.5)
Other
2 (5.1)
2 (1.5)
Marital Status
.296
Married
20 (51.3)
79 (62.7)
Divorced
4 (10.3)
9 (7.1)
Widowed
11 (28.2)
17 (13.4)
Single
4 (10.3)
18 (14.3)
Other
3 (2.4)
Employment
.004
Retired
30 (76.9)
63 (50)
Not Retired
9 (23.1)
62 (49.6)
Full-time
5 (12.8)
30 (23.8)
Part-time
1 (2.6)
3 (2.4)
Unemployed
2 (5.1)
8 (6.3)
Disabled
0
10 (7.9)
Other
1 (2.6)
11 (8.7)
Insurance status
.021
Private
9 (23)
59 (46.8)
Federal
27 (69.2)
64 (50.8)
Median household income 55,226 [48,151-70,552]
57,455 [49,796-70,580]
.785
Note. IQR = interquartile range; BMI = body mass index. a Patients with diabetes vs.
patients without diabetes by Mann-Whitney U, chi-squared (χ2), or Fisher’s exact tests;
BMI=body mass index
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Table 3
Clinical Characteristics and Cancer Treatment in Patients With and Without Diabetes (N=165)

Preoperative glucose, mmol/L
(n=142)
Preoperative glucose >7.77 mmol/L
Cancer Stage
Stage II
Stage III
Diagnosed with metastatic disease
within 12 months of surgery
Stage II
Stage III

With diabetes
n=39(%) [IQR]
11.16 [9.72-11.56]
(n=38)
22 (57.9)

Without diabetes
n=126 (%) [IQR]
5.28 [5.06-6.39]
(n=104)
11 (10.6)

15 (38.5)
24 (61.5)
0

67 (53.2)
59 (46.8)
6 (4.7)

Pa
value
<.001
<.001
.108

2 (1.6)
4 (3.1)

Chemotherapy Treatment
Cycles received

12 (30.8)
12 [11.5-12] (n=12)

46 (36.2)
11.5 [9-12] (n=46)

Radiation therapy
Number of oral diabetes medications
One
Two
Diabetes Therapy at Time of Surgery
Insulin
Oral therapyb
Insulin and oral therapy
Metformin at surgery
Steroid dose over one month
following surgery, prednisolone
equivalent
Steroid dose over 12 month
following surgery (Prednisolone
equivalent)

1 (2.6)

4 (3.1)

14 (35.9)
2 (5.1)

0
0

14 (35.9)
16 (41)
5 (12.8)
7 (17.9)
50 [25-62] (n=11)

0
0
0
1 (.01)c
60 [50-100] (n= 24)

<.001
<.001
<.001
<.001
.862

112 [53-808]
n=11

1551 [68.5-2367.5]
n=24

.044

34 (87.2)
0
3 (7.7)
2 (5.1)

98 (77.81)
13 (10.3)
7 (5.5)
8 (6.3)

Antibiotic use over 12 months
None
One
Two
Three or more

.532
.264
<.001

.199

Positive Blood Cultures within one
1 (2.6)
2 (1.6)
.557
month following surgery
Positive Blood Cultures within 12
1 (2.6)
5 (3.9)
.682
months following surgery
Note. aPatients with diabetes vs. patients without diabetes by Mann-Whitney U, chisquared (χ2), or Fisher’s exact tests; bDipeptidyl Peptidase-4 (DPP-4) inhibitors, Metformin,
Sodium-glucose co-transporter-2 (SGLT2) inhibitors, Sulfonylureas; cMetformin prescribed for
pancreatic insufficiency
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Table 4
Comparison of Mean Glucose, Standard Deviation (SD), and Coefficient of Variation (CV)
Between Patients With and Without Diabetes Within One Year Following Surgery (Median and
IQR) N=165)
With Diabetes median, [IQR]
n=39

Without Diabetes median, [IQR]
n=126

Pa
value

30.00 [16.5-46.50] (n=39)
49.50 [23.00-64.50] (n=39)

9 [4.50-17] (n=126)
20.5 [10.00-43.50] (n=126)

<.001
<.001

Mean Glucose mmol/Lb
One Month
8.45 [7.17-10.33] (n=36)
One Year
8.46 [7.35-11.24] (n=39)

6.50[6.03-6.94] (n=112)
6.41 [5.89-6.92] (n=126)

<.001
<.001

SD mmol/L b
One Month
One Year

1.14 [.79-1.56] (n=104)
1.19 [.86-1.6] (n=126)

<.001
<.001

Mean # of Glucose
Measurements (n)b
One Month
One Year

2.48 [1.69-2.98] (n=36)
2.5 [1.81-3.29] (n=36)

CV b
One Month
27.40 [20.11-31.04] (n=39)
17.53 [12.37-22.68] (n=104)
<.001
One Year
29.04 [24.63-33.34] (n=39)
18.60 [13.98-22.68] (n=126)
<.001
Note. Glycemic variability was determined by the SD (mmol/L) and CV. CV was calculated using
the formula of %: (SD÷Mean)x100 (Ceriello et al., 2019; Danne et al., 2017). IQR = interquartile
range. aWith diabetes vs. without diabetes by Mann-Whitney U. bTukey’s hinges
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Table 5
Spearman’s Correlation Coefficients Between Demographic and Clinical Characteristics and Mean Glucose, Standard Deviation (SD),
and Coefficient of Variation (%CV) in Patients With Diabetes (n=39)
One month
mean glucose
.108

One
month SD
.107

One month
%CV
-.044

One year
mean glucose
-.028

One year SD

One year %CV

-.045

-.217

BMI

-.098

-.413*

-.481**

.048

-.221

-.319

Gendera

.321

.246

.134

.433**

.360*

.119

Raceb

-.409*

-.452**

-.294

-.284

-.259

-.069

Geographic regionc

-.047

-.070

-.012

-.041

-.124

-.072

Employment statusd

.019

-.101

-.135

.099

.108

.151

Marital statuse

-.226

-.178

-.113

-.324

-.342*

-.201

Insurance statusf

-.089

-.104

-.089

.028

.003

-.003

Median Household Income

.114

.023

-.055

.156

.213

.172

Preoperative glucose

.311

.197

.038

.518**

.448**

.279

Preoperative glucose > 7.77
mmol/L

.225

.126

.011

.442**

.413**

.296

-

-

-

-

-

-

Received chemotherapyg

-.113

-.269

-.310

.143

-.079

-.158

Received radiation therapyg

.268

.268

.138

.274

.058

-.231

Age at surgery

Metastatic disease within one
year of surgeryg
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Table 5 Continued
Spearman’s Correlation Coefficients Between Demographic and Clinical Characteristics and Mean Glucose, Standard Deviation (SD),
and Coefficient of Variation (%CV) in Patients With Diabetes (n=39)
One month
mean glucose
-.270

One
month SD
-.280

One month
%CV
-.104

One year
mean glucose
-.428

One year SD

One year %CV

-.206

.161

Cumulative steroid dose one year
following surgery

-.619**

-.639**

-.247

-.291

-.302

.031

Taking insulin at time of surgeryg

.389*

.335*

.176

.318*

.294

.104

Taking insulin one year following
surgeryg

.355*

.236

.106

.338*

.375*

.292

Positive blood culture within one
month following surgery g

-.106

-.236

-.252

-.101

-.245

-.259

Positive blood culture within one
year following surgeryg

-.106

-.236

-.252

-.101

-.245

-.259

Cumulative steroid dose one
month following surgery

Number of antibiotics prescribed
-.026
-.150
-.183
-.113
-.039
.024
within one month following
surgery
Number of antibiotics prescribed
-.114
-.126
-.051
-.286
-.151
.017
within one year following surgery
Note. aFemale = 0, male = 1. bCaucasian = 0, non-Caucasian = 1. cMidwest = 0, other = 1. dRetired = 0, working = 1, other = 2. eMarried
= 0, not married = 1. fFederal = 0, private = 1. gNo = 0, yes = 1.
* p<.05. ** p<.01.
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Table 6
Spearman’s Correlation Coefficients Between Demographic and Clinical Characteristics and
Mean Glucose, Standard Deviation (SD), and Coefficient of Variation (%CV) in Patients Without
Diabetes (n=126)
One month
mean
glucose
.197*

One
month
SD
.227*

One
month
%CV
.183

BMI
Gendera
Raceb
Geographic regionc

-.002
.017
-.128
-.008

-.017
-.171
-.047
.065

-.019
-.155
-.029
.068

.135
-.002
-.080
-.074

.105
-.125
.022
.034

.081
-.109
.056
.076

Employment statusd

-.142

-.119

-.066

-.185

-.079

-.054

.130

.121

.115

.210*

.158

.129

Insurance statusf

-.195*

-.197*

-.166

-.199*

-.186*

-.185*

Median Household Income

-.046

-.112

-.102

-.177

-.135

-.107

Preoperative glucose

.399**

.155

.065

.359**

.137

.041

.166

.054

-.003

.168

.099

.034

-.167

-.191

-.146

-.242**

-.177*

-.157

*

.168

.078

Age at surgery

Marital status

e

Preoperative glucose > 7.77
mmol/L
Received chemotherapyf
Received radiation

f

One year
One
mean
year SD
glucose
.268**
.206*

One year
%CV
.174

.182

.230

.095

.331

Metastatic disease within
one year of surgeryf

-.005

.182

.197*

-.036

.112

.129

Cumulative steroid dose one
month following surgery
Cumulative steroid dose one
year following surgery
Positive blood culture within
one month following
surgery
Positive blood culture within
one year following surgery
Number of antibiotics
prescribed within one
month following surgery
Number of antibiotics
prescribed within one year
following surgery

-.041

-.066

-.049

-.023

.022

.038

-.212

-.215

-.182

-.204

-.147

-.127

-.006

.012

.009

.016

-.017

-.017

-.126

.011

.070

.012

.148

.167

.132

.216*

.194*

.121

.139

.122

.104

.156

.145

.107

.176*

.184*

Note. aFemale= 0, male = 1. bCaucasian = 0, non-Caucasian = 1. cMidwest = 0, other = 1.
d
Retired = 0, working =1, other = 2. eMarried = 0, not married = 1. fFederal = 0, private = 1. gNo
= 0, yes = 1.
* p<.05. ** p<.01.
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Glycemic Variability in Patients with Stage II-III Colon Cancer
Treated with Surgery and Adjuvant Chemotherapy
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Abstract
OBJECTIVES: To examine glycemic variability within one month following surgery, throughout
adjuvant chemotherapy, and within one year following surgery among patients, with and
without Type 2 Diabetes, treated for stage II-III colon cancer.
SAMPLE AND SETTING: 58 patients with stage II-III colon cancer treated with surgery and
chemotherapy in the midwestern United States.
METHODS & VARIABLES: A retrospective analysis of electronic health record (EHR) data over one
year was used. The main outcome was glycemic variability, measured as standard deviation (SD)
and % coefficient of variation (CV).
RESULTS: Patients with diabetes had higher glycemic variability throughout chemotherapy and
within one year following surgery compared to those without diabetes. A significant change in
glycemic variability throughout chemotherapy was observed in patients without diabetes.
Significant associations between glycemic variability and demographic/clinical characteristics
were observed; associations differed by diabetes status, SD, and CV.
IMPLICATIONS FOR NURSING: This study informs oncology nurses of methods of
assessing glycemic control using glycemic variability. Nurses need to assess serial blood glucoses
in patients with and without diabetes. Teaching patients how to maintain glycemic control
during cancer treatment is a priority. Future research should include predictive models to
identify risk factors for higher glycemic variability and cancer-related symptoms/outcomes.
Keywords: chemotherapy, colon cancer, glucose, glycemic variability, steroids, surgery
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Introduction and Background
Patients with cancer, with and without diabetes, are known to experience
hyperglycemia which has been associated with poor cancer related outcomes (Hammer et al.,
2019; Healy et al., 2017; Simon et al., 2018; Zylla et al., 2019). Glycemic control in patients with
cancer has become an area of great interest. The incidence of diabetes in the U.S. is 10.5%
(Centers for Disease Control and Prevention, 2020) and has been reported to occur in up to 29%
of patients with cancer (Barone et al., 2010). In addition, patients with diabetes are known to
have a 27% higher risk of developing colon cancer compared to individuals without diabetes
(Gonzalez et al., 2017). Diabetes rates in the U.S. are expected to rise from 35.6 million cases in
2015 to 54.9 million by 2030 (Rowley et al., 2017) and it is anticipated that the rates of
individuals with both diabetes and cancer will similarly increase.
In 2020, an estimated 104,610 new cases of colon cancer will be diagnosed in the U.S.
(American Cancer Society, 2020). High-risk stage II and stage III colon cancers are treated with
surgery followed by curative intent adjuvant chemotherapy (National Comprehensive Cancer
Network, 2020). The five year survival rates for colon cancer have improved to 90% for localized
(stage I-II) and 71% for regional (stage III) disease (American Cancer Society, 2020). Patients with
diabetes and colorectal cancer have a 17% increased risk of all-cause mortality and a 12%
increased risk of cancer-specific mortality (Mills et al., 2013).
There are no established, specific guidelines for diabetes management in patients with
cancer and no standard for glycemic control in patients with cancer. Hemoglobin A1c (HbA1c),
the most commonly used assessment of glycemic status, provides a value that reflects a 2-3
month average of blood glucose (American Diabetes Association, 2020). HbA1c does not capture
glycemic variability, described as fluctuations in blood glucose. Hyperglycemia, hypoglycemia,
and glycemic variability are perturbations in blood glucose collectively termed malglycemia
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(Hammer et al., 2009). Similarly, dysglycemia is post-prandial perturbations in blood glucose
(Ceriello et al., 2019). Optimal glycemic control in patients with diabetes, assessed with HbA1c,
can only be achieved when there is a simultaneous reduction in glycemic variability (Kovatchev,
2019). In patients with cancer, HbA1c measures may be inaccurate due to the malignancy, acute
blood loss from surgery, and the apoptotic effect of chemotherapy on the life of erythrocytes
(Campbell et al., 2019; Fayyaz et al., 2019; Gu et al., 2018). Glycemic variability can be captured
through repeated measures of blood glucose and reported as short-term (within-day/betweenday) and long-term (visit-to-visit) variability for a more accurate assessment of glycemic control
in patients with cancer (Monnier et al., 2018).
Blood glucose is an essential indicator of health (Ceriello et al., 2019; Hammer et al.,
2009; Suh & Kim, 2015) and glycemic control is important in patients who are hospitalized and
those receiving ambulatory care services (American Diabetes Association, 2020). The
associations between hyperglycemia and cancer have been studied and reviewed for decades
(Giovannucci et al., 2010; Hammer et al., 2019). Little is known about glycemic variability in
patients with cancer and no known studies have evaluated glycemic variability among patients
treated with curative intent surgery followed by chemotherapy. Patients with colon cancer, the
fourth most commonly diagnosed cancer in the U.S. (American Cancer Society, 2020), are an
ideal population to study glycemic variability because of the known associations with metabolic
syndrome (Bowers et al., 2006), insulin resistance (Fujihara et al., 2012), and decreased diabetes
medication adherence (Zanders et al., 2018).
Glycemic variability occurs in patients with and without diabetes; however, it has been
reported to be higher in patients with diabetes (Gude et al., 2017; Mandolfo et al., 2020; Suh &
Kim, 2015). Higher mortality in patients with congestive heart failure, in critically ill and
hospitalized patients, and within 30 days following surgery has been associated with increased
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glycemic variability in the general population (Akirov et al., 2019; Atamna et al., 2019; Gu et al.,
2018; Singh et al., 2018). Additional adverse outcomes associated with increased glycemic
variability include vascular complications (Gorst et al., 2015), diabetic neuropathy (Cheng et al.,
2014; Lai et al., 2019), end stage renal disease (Yang et al., 2015), and cognitive decline (Yu et
al., 2019). There is limited research on the associations of glycemic variability and demographic
characteristics such as age, gender, race, body mass index (BMI), and socioeconomic status.
Many demographic characteristics are known to influence outcomes in patients with diabetes
and studies of associations between demographic characteristics and glycemic variability are
needed (American Diabetes Association, 2020).
There are numerous methods of reporting glycemic variability but only two methods,
standard deviation (SD) and % coefficient of variation (CV), have suggested cut-points that
indicate levels that increase risks for adverse events. A SD of >29 mg/dL has been reported as
high glycemic variability in patients with hematologic cancers receiving allogeneic hematopoietic
cell transplantation (Hammer et al., 2009). The value of 36% CV, computed by % (SD ÷ mean
glucose) x 100 was recently accepted as a value that separates stable or unstable glycemic
control in patients with diabetes using a continuous glucose monitor (Ceriello et al., 2019;
Danne et al., 2017; Monnier et al., 2018). An integrative review of 19 studies that evaluated
glycemic variability in patients with gastrointestinal cancers found that SD but not CV had been
used to evaluate glycemic variability (Mandolfo et al., 2020). In addition, only two studies in the
review included patients who received chemotherapy and/or radiation therapy and these were
limited to gastric cancer (Gemici et al., 2013; Kandaz M et al., 2017). The integrative review
underscores the gap in understanding glycemic variability in patients with gastrointestinal
cancer.
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Investigations of glycemic variability across cancer diagnoses are limited. High glycemic
variability as defined by Hammer et al., (2009) of SD >29 mg/dL was associated with a hazard
ratio of 1.2 for risk of infection and at levels of >90 mg/dL there was a 4-fold increased mortality
risk in patients treated with allogeneic hematopoietic cell transplantation. In patients with Acute
Myelogenous Leukemia (AML), high glycemic variability was associated with lower remission
rates in all patients and reduced survival in those over the age of 60 (Kuhlman et al., 2019).
Glycemic variability has been associated with increased risk for a cancer diagnosis in healthy
individuals with and without diabetes (Kobayashi et al., 2020; Saito et al., 2019). To our
knowledge, there are no published studies of patients with stage II-III colon cancer treated with
adjuvant chemotherapy that investigated glycemic variability after surgery and throughout
chemotherapy.
Objectives
The purpose of this study was to examine glycemic variability within one month
following surgery, throughout adjuvant chemotherapy, and within one year following surgery
between groups of adult patients, with and without diabetes, treated for stage II-III colon
cancer. The specific aims were to: 1) Determine levels of glycemic variability between groups; 2)
Analyze associations between glycemic variability and preoperative diabetes and preoperative
glucose values; and 3) Examine associations between glycemic variability and demographic
characteristics, clinical characteristics, and positive blood cultures.
Methods
Design
This was a descriptive, correlational, longitudinal, retrospective analysis of electronic
health record (EHR) data of patients with stage II-III colon cancer treated with chemotherapy.
The conceptual model supporting this study was derived from the Malglycemia Orbit Model
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(Hammer & Voss, 2012). This original model describes the complex associations between
malglycemia (hypoglycemia, hyperglycemia, and glycemic variability) and multiple factors in
individuals with cancer. The Conceptual Model of Hyperglycemica In a Patient With Cancer
offered additional support by describing the numerous biological, physiological, and intracellular
pathways that contribute to and are impacted by hyperglycemia in patients with cancer
(Hammer et al., 2019).
Sample and Setting
All patients in the sample (N=58) were treated at a single, 809-bed university affiliated
tertiary medical center and National Cancer Institute (NCI) designated cancer center. A cancer
center registry, which collects data on all the patients diagnosed and/or treated for cancer at
the affiliated institutions, identified all patients for inclusion with stage II-III colon cancer
diagnosed between August 1, 2012 and November 30, 2018. Inclusion criteria was an age over
19 years, a diagnosis of stage II-III colon cancer, record of administration of a 5-Fluorouracil
based chemotherapy regimen, and two or more glucose values in the EHR within one year
following colon surgery. Patients were excluded if they were being actively treated with
chemotherapy for a malignancy other than colon cancer, had a diagnosis of Type 1 Diabetes
Mellitus, or had only one glucose value in the EHR within one year following surgery. The
American Joint Committee on Cancer (AJCC) staging criteria was used to classify patient’s stage.
IRB approval was obtained and an EHR query was performed to retrieve data from all patients
identified by the cancer center registry during the specified time.
Methods and Variables
The institution used EPIC as the EHR (Epic Corporation, Verona, WI). The EHR codes that
were specific for variables in our study were identified with the assistance of the department of
clinical and translational research, who also completed the data extraction. Table 1 displays all
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data extracted for demographic and clinical characteristics, preoperative diabetes status,
glucose values, and cancer treatment information. The ICD-CM-10 codes of E08-E13, obtained
from the EHR, were used to determine diabetes status. The diabetes status was confirmed by
cross-referencing the EHR. Additionally, the EHR was searched to confirm the diagnosis of
diabetes on all patients who did not have an ICD-CM-10 code for diabetes but had a
preoperative glucose value of 140 mg/dL or were listed as taking oral diabetes therapy and/or
insulin. All positive blood culture results were counted as blood stream infections. Zip codes
were used to retrieve the household income from the 2018 US Census Bureau data (US Census
Bureau, 2018)
The outcome variable was glycemic variability, which was computed using the glucose
values extracted from the EHR and reported as SD (mg/dL) and CV (%) as described in Table 1.
Computation of SD was performed using SPSS 26 (IBM Corporation, Armonk, NY, USA; 2017)
and CV was calculated by using the formula of %: (SD÷Mean)x100 (Monnier et al., 2017). The
principal investigator (N.M) searched the EHR to collect missing data, recoded variables, sorted
and cleaned the data, and also computed the analyses. An attempt to identify results for missing
data was performed by searching the EHR. Missing data were counted as null values. Data
cleaning, file management, and statistical analyses were performed by N.M. with guidance and
confirmation by our co-author, L.S.
Statistical Analysis
Data analyses were performed using SPSS 26. Within and between group analyses were
performed on the sample of patients who met the inclusion criteria. Assessment of normality
was conducted using the Kolmogorov-Smirnov test. Continuous variables were presented as
medians (interquartile range; IQR). The median represents the 50% quartile and the IQR reports
the 25% and 75% quartiles (Field, 2018). Categorical variables were presented by (N, %). The
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Mann-Whitney U test was used to compare continuous variables. The chi-squared (χ2) or
Fisher’s exact test was used to compare categorical characteristics between groups of patients
with and without diabetes; results are reported as numbers and percentages. A Friedman Test
was used to examine a change in glycemic variability over time in patients who received 12
cycles of chemotherapy. Spearman’s correlation analysis was used to determine correlation
coefficients. Statistical significance was set at p <.05.
RESULTS
Baseline Demographic Characteristics
All sample baseline demographic and clinical characteristics are in Table 2 and 3,
respectively. The sample included patients with stage II-III colon cancer (N=58) who were
treated with surgery and chemotherapy. In total, 2,311 glucose values were retrieved. Almost
21% (n=12) had a prior diagnosis of diabetes. Patients with diabetes were older than those
without diabetes with a mean age of 66.1+/-10.4 years compared to 55.6+/-13 years in those
without diabetes (p=.025). There were no statistical differences in median values between the
groups of patients with and without diabetes in regard to gender, body mass index (BMI), race,
and geographic region, employment, insurance, and income.
Baseline Clinical Characteristics
The preoperative glucose value was higher in patients with diabetes compared to
patients without diabetes (p<.01). A higher percent of patients with diabetes had a preoperative
glucose value of >140 mg/dL compared to patients without diabetes; however, differences were
not statistically significant. All patients received a 5-Fluouracil based chemotherapy regimen
with a median (IQR) number of 12 cycles of adjuvant chemotherapy in patients with and without
diabetes. The diabetes therapy at the time of surgery included insulin (25%, n=3), oral therapy
(25%, n=3), or combined insulin and oral therapy (8.3%, n=1). There were no significant
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differences in patients with and without diabetes in the cancer stage, type of chemotherapy
regimen, radiation therapy, cumulative steroid dose throughout chemotherapy and one month
or one year following surgery, positive blood cultures, or presence of metastatic disease within a
year of colon cancer surgery.
Glycemic Variability and Adjuvant Chemotherapy in Patients With and Without Diabetes
Table 4 describes results of Aim 1, showing differences in the number of glucose
measurements, mean glucose, SD, and CV between groups of patients with and without
diabetes within one month following surgery, throughout adjuvant chemotherapy, and within
one year following surgery. Patients with diabetes had 3.5 times more glucose measurements
than those without diabetes over a year following surgery (p=.013), higher mean glucose
(142.75 mg/dL vs 115.75 mg/dL), SD (28.62 mg/dL vs 17.46 mg/dL), and CV (21.05% vs 15.21%)
within one month following surgery. They also experienced higher mean glucose (153.41 mg/dL
vs 107.7 mg/dL), SD (42.69 mg/dL vs 18.81 mg/dL), and CV (26.73 mg/dL vs 16.37 mg/dL) within
one year following surgery (p<.001) compared to those without diabetes. Higher mean glucoses
were observed throughout adjuvant chemotherapy in patients with diabetes between cycle 1-4
(175.58 mg/dL vs 107.28 mg/dL), cycle 1-8 (195.25 mg/dL vs 106.7 mg/dL), cycle 1-12 (179.83
mg/dL vs 106.38 mg/dL), and cycle 1-last cycle (210.75 mg/dL vs 108.78 mg/dL) (p<.001).
Patients with diabetes also had significantly higher glycemic variability, as measured by SD and
CV, throughout chemotherapy compared to those without diabetes. Specifically, the SD was
significantly higher in patients with diabetes during chemotherapy between cycle 1-4 (36.59
mg/dL vs 9.19 mg/dL), cycle 1-8 (36.47 vs 15.17 mg/dL), cycle 1-12 (38.59 mg/dL vs 15.59
mg/dL), and cycle 1-last cycle (43.20 mg/dL vs 16.69 mg/dL) (p<.001). CV was significantly higher
in patients with diabetes during chemotherapy between cycle 1-4 (22.3% vs 8.69%) (p=.009),
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cycle 1-8 (22.76% vs 13.36%) (p=.008), cycle 1-12 (20.7% vs 13.36%) (p=.004), and cycle 1-last
cycle (19.57% vs 15.12%) (p<.001).
Figure 1 displays the changes in glycemic variability throughout chemotherapy
treatment for patients who received 12 cycles of chemotherapy (n=29). In patients with
diabetes (n=8), there were no significant differences in SD and CV throughout treatment of 12
cycles of chemotherapy. A significant increase in glycemic variability as measured by SD (p=.013)
and CV (p=.001) throughout treatment of 12 cycles of chemotherapy was observed in patients
without diabetes (n=21).
Associations Between Glycemic Variability During Adjuvant Chemotherapy and Preoperative
Diabetes, Preoperative Glucose, and Pre-chemotherapy Glucose
Table 5 shows results of Aim 2 using the Spearman’s correlation coefficient of the
associations between glycemic variability as measured by SD and CV and preoperative diabetes,
preoperative glucose, and pre-chemotherapy glucose. Having a preoperative diagnosis of
diabetes was significantly associated with higher mean glucose and higher glycemic variability at
every interval assessed during chemotherapy treatment. A higher preoperative blood glucose
value was associated with a higher subsequent blood glucose value at one month following
surgery, one year following surgery, and throughout adjuvant chemotherapy at cycle 1, 4, 8, and
12. The pre-chemotherapy blood glucose value was not associated with blood glucose values at
cycle 1, 4, 8, or 12 of adjuvant chemotherapy.
Associations With Demographic Characteristics in Patients With Diabetes
Significant associations for Aim 3 were found between demographic characteristics and
glycemic variability in patients with diabetes, as shown in Table 6. Younger age was significantly
associated with higher SD (r= -.648) and CV (r= -.661) between cycle 1-4. Increased BMI was
significantly associated with higher SD (r=.900) and CV (r=.900) between cycle 1-8 and C1-12
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(r=1). Caucasian race was significantly associated with higher one month SD (r= -.646) and CV (r=
-.646). Being married was significantly associated with higher one year SD (r= -.661). Glycemic
variability throughout the course of chemotherapy was not associated with race, marital status,
or gender.
Associations With Clinical Characteristics in Patients With Diabetes
Significant associations were found between clinical characteristics and glycemic
variability as shown in Table 7. Preoperative insulin use (r=.646) was significantly associated with
higher one month SD (r=.646). Insulin use at cycle 8 was associated with higher SD and CV
between cycle 1-8 (r=.822, r=.822), between cycle 1-12 (r=.756, r=.756), between cycle 1 – last
cycle (r=.657, r=.657), and one year SD (r=.615) and CV (r=.666). A fewer number of diabetes
medications taken at the time of the last cycle of chemotherapy was associated with higher one
month CV (r= -.696). A lower cumulative steroid dose over one year was significantly associated
with higher one month SD (r= -.762) and one month CV (r= -.810). A lower cumulative steroid
dose over the entire course (Cycle 1- last cycle) of chemotherapy was associated with a higher
one month CV (r= -.782).
No associations were noted between glycemic variability and cancer stage, number of
chemotherapy cycles, radiation therapy, or the number of diabetes medications taken at
initiation of chemotherapy.
Associations in Patients Without Diabetes
The only significant associations in patients without diabetes were found between
glycemic variability, as measured by SD and CV, and marital status. Not being married was
associated with higher SD between cycle 1 - last cycle of chemotherapy (r=.323, p<.01), one year
SD (r=.396, p<.05), and one year CV (r=.376, p<.05). No significant associations were noted
between glycemic variability and all other demographic and clinical characteristics.
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Discussion
To our knowledge, this was the first study to examine long-term glycemic variability
throughout adjuvant chemotherapy and for one year following surgery in patients, with and
without diabetes, treated for stage II-III colon cancer. Results of Aim 1 were that patients with
preoperative diabetes had higher glycemic variability throughout adjuvant chemotherapy and
for one year following surgery compared to patients without diabetes. Aim 2’s results were that
preoperative diagnosis of diabetes was associated with higher glycemic variability, as measured
by SD and CV, within one month following surgery, throughout chemotherapy treatment, and
within one year following surgery. Aim 2 also found that preoperative glucose value, but not the
pre-chemotherapy glucose value, was associated with glycemic variability, as measured by SD,
one month and one year following surgery but not throughout chemotherapy. Results of Aim 3
identified several significant associations between glycemic variability and multiple demographic
and clinical characteristics in patients with diabetes, but only with marital status in patients
without diabetes. These findings support knowledge that glycemic variability and
hyperglycemia, two critical components of malglycemia, represent two separate clinical factors
(Ceriello et al., 2019; Hammer et al., 2009). We must acknowledge that glycemic control is
optimized with reduction in glycemic variability (Kovatchev, 2019).
Aim 1 results were that patients with diabetes prior to surgery had higher preoperative
glucose, preoperative hyperglycemia, and higher pre-chemotherapy glucose compared to
patients without diabetes. Patients with diabetes also had significantly higher glycemic
variability throughout chemotherapy at each assessment. These findings are consistent with the
literature suggesting that patients with diabetes have higher glycemic variability compared to
those without diabetes (Gude et al., 2017; Mandolfo et al., 2020; Suh & Kim, 2015). Patients
without diabetes experienced a significant change in glycemic variability over the course of
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completing 12 cycles of chemotherapy, despite experiencing overall lower glycemic variability
compared to those with diabetes.
No specific guidelines exist for the management of glycemic control in patients with
cancer. Results of Aim 2 indicate that the group of patients with stage II-III colon cancer with
diabetes had high glycemic variability as per the high cut-point values of >29 mg/dL SD reported
by Hammer et al. (2009), and very high upper limit interquartile ranges over the course of 12
cycles of chemotherapy. The median CV measurements throughout the course of chemotherapy
did not exceed 36% in patients regardless of diabetes status; however, we did note high upper
limit interquartile ranges between cycle 1 -12 in patients with diabetes. The measurement of SD
or CV using serial blood glucoses can be used to assess glycemic control throughout adjuvant
chemotherapy treatment (Ceriello et al., 2019; Kovatchev, 2019; Peyser et al., 2018). A benefit
of using SD or CV is that blood glucose values are not affected by the life of the erythrocytes,
unlike HbA1c (Campbell et al., 2019; Fayyaz et al., 2019). Further research is needed to
determine the metric for high glycemic variability, as measured by SD and CV, in patients with
cancer with and without diabetes.
There are limited data of associations between glycemic variability and demographic
characteristics in patients with colon cancer. Results of Aim 3 found that in patients with
diabetes there were significant associations between glycemic variability and demographic and
clinical characteristics. Specifically, our study identified that younger age was strongly associated
with higher SD and CV in patients with diabetes between cycle 1-4 of chemotherapy. This finding
differs from the positive association between age and glycemic variability noted in the general
population (Gude et al., 2017). It is possible that the younger patients with diabetes had other
health conditions, such as obesity, that could have influenced glycemic variability in this study.
Associations between increased glycemic variability and lower BMI have been reported in
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patients with (Wang et al., 2017) and without diabetes (Gude et al., 2017), but our study
identified that higher CV between cycle 1-8 and cycle 1-12 of chemotherapy was strongly
associated with higher BMI in patients with diabetes. Few studies have evaluated associations
between race and glycemic variability, and study findings have been inconsistent (EchouffoTcheugui et al., 2019; Hill et al., 2011; Kim et al., 2014). We identified that Caucasian race was
strongly associated with higher one month glycemic variability, as measured by SD and CV, in
patients with diabetes. These results should be interpreted with caution as our study included
very few non-Caucasian patients.
In addition, we found that 25% of patients with diabetes were taking insulin and
another 25% were only taking oral diabetes therapy at the time of surgery. Insulin therapy is
typically reserved for patients with uncontrolled diabetes; therefore, we were not surprised that
the use of insulin at cycle 8 of chemotherapy was strongly associated with glycemic variability
between cycle 1-8 and cycle 1-12. Lower one month CV was strongly associated with a higher
number of oral diabetes medications taken at the completion of chemotherapy. Further studies
are warranted evaluating the influence of insulin and oral diabetes medications on glycemic
variability in patients with colon cancer who receive chemotherapy.
Steroid treatment, commonly prescribed as a chemotherapy premedication, results in
hyperglycemia and increased risk for infections (Clement et al., 2004; Zylla et al., 2019). We
found higher one-month glycemic variability associated with lower cumulative steroid dose
throughout chemotherapy and over one year following surgery. Patients with poorly controlled
diabetes and higher glycemic variability before initiation of chemotherapy may have
intentionally been prescribed by clinicians fewer steroids and lower cumulative steroid doses.
Further investigation is warranted. We also attempted to investigate the associations between
positive blood cultures and glycemic variability. We were unable to identify this association
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because no patients with diabetes, and very few patients without diabetes, experienced positive
blood cultures within a year following surgery.
Strengths and Limitations
The use of EHR provided an opportunity to collect information on a large number of
patients in an efficient, timely, cost-savings manner (Casey et al., 2016). Challenges of EHR
research include concerns of the accuracy of data entry; however, glucose levels, prescriptions,
and chemotherapy orders were automatically imputed into the EHR mitigating the risk of error.
We believe that the small sample size of patients with diabetes who completed 12 cycles of
chemotherapy (n=8) limited our ability to identify significant changes in glycemic variability over
time in patients with diabetes.
The ability to study 2,311 glucose values over a year in 58 patients treated with adjuvant
chemotherapy for stage II-III colon cancer is a strength. All but two patients, one with and one
without diabetes, had more than one glucose value throughout adjuvant chemotherapy. We
were able to identify chemotherapy dose reductions and delays and calculate the cumulative
steroid dose throughout chemotherapy and over a year following surgery. The use of the EHR
provided the opportunity to follow a patient’s trajectory throughout adjuvant chemotherapy
treatment and within one year following surgery.
We encountered inherent threats of retrospective longitudinal studies, which may
include selection bias regarding chemotherapy treatment decisions, inaccurate information in
the EHR, missing data, and use of unmatched groups (Casey et al., 2016; Gordis, 2014). The
datasets were limited to patients from a single institution, and the majority of the patients were
Caucasian and from the Midwest. Not all patients completed 12 cycles of adjuvant
chemotherapy, the decision was made a priori to include the entire sample of patients in the
EHR to inform future research. Despite searching to retrieve missing data from the EHR, we
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realize there may be patients with diabetes or pre-diabetes that were not identified. Glucose
values were assumed to be random and the timing of meals in relation to the timing of the test
was not captured in the EHR. Furthermore, the EHR problem list provided limited information as
it does not include dates of diagnoses. Information on nutritional status also was limited and
BMI was the only nutritional status indicator collected. Lastly, our data were not normally
distributed, which limited our ability to perform multiple regression analyses and identify
confounding variables. We believe that the benefits of knowledge gained outweigh the
limitations of conducting this retrospective study.
Implications
Nursing practice
We know that glycemic variability is associated with complications such as infection,
lower remission rates, and mortality in patients with hematological malignancies (Hammer et
al., 2009; Hammer et al., 2016; Kuhlman et al., 2019). Oncology nurses should be aware that, in
the general population, patients with diabetes have higher glycemic variability compared to
those without diabetes. Our findings show this to be true in patients with a solid tumor
malignancy, colon cancer. Oncology nurse clinicians need to discuss the importance of glycemic
control with patients with colon cancer when providing pre-chemotherapy teaching. Nutrition,
glycemic control, and glycemic variability should be included in the assessment of patients
diagnosed with diabetes and colon cancer. It is important to know, as our study reported, that
patients may experience increased glycemic variability despite having a normal blood glucose
value prior to initiation of chemotherapy. We cannot rely on a single pre-chemotherapy glucose
value to estimate glycemic variability throughout adjuvant chemotherapy. Essentially, all
patients with stage II-III colon cancer are at risk for increased glycemic variability throughout
adjuvant chemotherapy. Blood glucose values should be monitored, and glycemic variability
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calculated as a more complete assessment of glycemic control in patients receiving
chemotherapy.
Research
Findings from our study provide insight and direction on glycemic variability in patients
with colon cancer. Future research using predictive models to identify risk factors for higher
glycemic variability and cancer-related symptoms/outcomes in a variety of solid tumor
malignancies can contribute to the development of guidelines for improved glycemic control.
Investigations of biomarkers, such as glycemic variability measures, in cancer symptom research
is consistent with the Oncology Nursing Society’s research priority to study symptom science
related to precision health and biosignatures (Von Ah et al., 2019).
Future studies of glycemic variability in patients with cancer should include investigating
multiple demographic and clinical characteristics that contribute to glycemic status. Assessment
should include comorbidities and related medications as well as the timing of glucose
assessments in relation to meals. Studies should include associations between diabetes selfmanagement and glycemic variability. Future research should consider the use of a continuous
glucose monitor and additional time points for assessment of glycemic variability (e.g., every
three months for one year), to further assess changes in glycemic variability over time. Future
studies should include larger sample sizes, longer follow-up, and cohorts of patients with solid
tumor malignancies (e.g., breast, lung, prostate, colon, gastric, esophageal, pancreatic,
hepatocellular, and ovarian cancer) to investigate associations between glycemic variability,
various tumor types, health care utilization (e.g., emergency room visits, hospitalizations, and
length of stay), and cancer-related outcomes including recurrence and overall survival.
Policy
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The American College of Surgeons Commission on Cancer recommends on-site nutrition
services by a registered dietician as part of optimal cancer care (American College of Surgeons,
2019). We advocate for cancer centers to offer nutrition counseling, including a diabetes selfmanagement assessment, to patients with diabetes before cancer treatment to promote
glycemic control. The American Nurses Association promotes the nurse’s role in care
coordination, which is an essential part of oncology nursing (American Nurses Association,
2020). We believe it is important for oncology nurses to participate in the multidisciplinary
management of glycemic control, to be aware of and support glycemic variability research, and
to advocate for policy change and development of glycemic variability guidelines in patients
with and without diabetes.
Conclusion
Our study identified that a group of patients with stage II-III colon cancer and
preoperative diabetes experienced higher glycemic variability within one month, throughout
adjuvant chemotherapy, and within one year compared to those without diabetes. We found
that patients without diabetes were vulnerable to significant increases in glycemic variability
throughout chemotherapy. Associations between glycemic variability, measured by SD and CV,
and demographic and clinical characteristics varied by preoperative diabetes status and method
of measurement. In patients with diabetes, we observed numerous strong associations
between glycemic variability and demographic and clinical characteristics. The measurement of
glycemic variability in patients treated with surgery and chemotherapy for stage II-III colon
cancer is feasible and provides another option for assessment of glycemic control in a setting
where the HbA1c may be unreliable.
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Knowledge Translation
•

Glycemic variability, described as fluctuations in glucose, can be calculated using serial
blood glucose values and reported as SD or CV to assess glycemic control in patients
with cancer receiving chemotherapy.

•

Patients with diabetes and stage II-III colon cancer experience higher glycemic variability
throughout adjuvant chemotherapy and within one year following surgery compared to
patients without diabetes.

•

Glycemic variability is associated with demographic and clinical characteristics in
patients with stage II-III colon cancer; associations differ among patients with and
without diabetes and by method of measurement (SD and CV).
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Table 1
Variable Descriptions and Timing of Measurements
Variable

Description

Aim

Demographic
Characteristics
Clinical
Characteristics
Diabetes

Age; BMI; Gender; Race; Geographic; Marital status; Employment; Insurance; Socioeconomic

3

Cancer stage; Metastatic disease within one year of surgerya; Prescription diabetes therapyb; Cumulative
steroid doseb; Blood culturesc.
Identified from the diagnosis code (ICD-CM-10) of E08-E13 from the EHR problem list and a search of
surgery notes and anesthesia records on all patients with preoperative glucose > 140 mg/dL or those on
diabetes therapy at the time of surgeryd.

3

Glucose Value

Random Blood Glucose Values Tested With Beckman Coulter AU5800 or Point of Care Tests: Glucose values
from the EHR, assumed to be non-fasting. Preoperative glucose value was the last glucose obtained prior to
surgery; pre-chemotherapy glucose value included last glucose obtained prior to start of chemotherapy.

1, 2, 3

Glycemic
Variability (GV)

Measurements: Standard Deviation (SD) and % coefficient of variation (CV). SD of glucose from the mean
was calculated with SPSS 26. CV of glucose was computed using the formula %: (SD÷Mean)x100 (Ceriello et
al., 2019; Danne et al., 2017; Monnier et al., 2017). Timing: GV was calculated using all available blood
glucose values within 30 days and within 15 months from the time of surgery in all patients. GV was
calculated between cycle 1, 4, 8, and 12 of chemotherapy. GV was also calculated between cycle 1 and the
date of the last cycle of chemotherapy to account for patients who did not complete 12 cycles of adjuvant
chemotherapy.
Date of colon cancer surgery and chemotherapy name, dose, and date of administration.

1, 2, 3

Cancer
Treatment
Chemotherapy
details

1, 2, 3

2, 3

Number of adjuvant chemotherapy cycles administered and examination of doses to identify dose
2, 3
reductions. Dates of chemotherapy administration were used to identify dates of cycle 1, 4, 8, and 12 and to
identify when patients experienced a delay in treatment. In patients who did not receive a total of 12 cycles
of chemotherapy, the date of the last cycle of chemotherapy was recorded.
Note. BMI = body mass index. aIdentified by search of electronic health record (EHR). bIncludes calculation of sum. cTo broadly capture
the occurrence of infections, we included documented positive blood cultures. dA preoperative glucose of >140 mg/dL represents
hyperglycemia in hospitalized patients (American Diabetes Association, 2020).
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Table 2
Baseline Demographic Characteristics, Median [IQR] in Groups of Patients With and Without
Preoperative Diabetes (N=58)

Age (years) *mean
Gender (male)
Body Mass Index (kg/m2)

With diabetes
n=12 (%)
66.1 +/-10.4 (n=12)
6 (50)
27.72 [26.37-30.86]
(n=7)

Without diabetes
n=46 (%)
55.6 +/-13.7 (n=46)
23 (50)
32.32 [27.86-41.10]
(n=29)

9 (75)
3 (25)

40 (87)
6 (13)

12 (100)
0

44 (95.7)
2 (4.3)

7 (58.3)
1 (8.3)
1 (8.3)
3 (25)
0

31 (67.4)
4 (8.6)
3 (6.5)
7 (15.2)
1 (2.2)

7 (58.3)
3 (25)
0
2 (16.7)
0
0

17 (36.9)
17 (36.9)
2 (4.4)
2 (4.4)
2 (4.4)
6 (13)

3 (25)
8 (66.7)

26 (56.5)
20 (43.4)

Pa value
.025
1
.236

Race
Caucasian
Non-Caucasian
Geographic region
Midwest
Other
Marital Status
Married
Divorced
Widowed
Single
Other
Employment
Retired
Full-time
Part-time
Unemployed
Disabled
Other
Insurance status
Private
Federal
Median household income

.374

1
.917

.292

.081

$51,473
$56,864
.969
[47234.5-61,268] (n=12)
[46,059.50-62,750] (n=45)
Note. a Patients with preoperative diabetes vs. patients without preoperative diabetes by
Mann-Whitney U, chi-squared (χ2), or Fisher’s exact tests.
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Table 3
Clinical Characteristics and Cancer Treatment in Groups of Patients With and Without
Preoperative Diabetes (N=58) (Median (Mdn) and Interquartile Range [IQR])
With diabetes
Mdn
n=12 (%)

IQR

Without diabetes
Mdn
IQR
n=46 (%)
91.5-142.5

Pa value

Preoperative glucose

208 (n=11) 152-212

99.5 (n=29)

.01

Preoperative glucose >140
mg/dL
Pre-Chemotherapy Glucose
(mg/dL)
Cancer Stage
Stage II
Stage III
Metastatic disease diagnosed
within 12 months of
surgery
Neoadjuvant Chemotherapy
Chemotherapy Regimen
FOLFOX/CAPEOX/FOLFIRI
5-FU or Capecitabine only
FOLFOX + Immunotherapy
Number of cycles
Oxaliplatin discontinued
Chemotherapy dose reduced
Chemotherapy dose delay
Radiation therapy
Cumulative steroid dose
(prednisolone equivalent in
mg)
Cycle 1-4
Cycle 1-8
Cycle 1-12
Cycle 1 to last cycle

6 (50)

7 (15.2)

.067

111 (n=10) 96-153

103.5 (n=40) 91.5-108

.083

0
12 (100)
0

7 (15.2)
39 (84.8)
4 (8.5%)

0

2 (4.3)

.325

.095
9 (75)
0
1 (8.3)
12
2 (16.7)
8 (66.7)
3 (15)
1 (8.3)

186 (n=8)
434 (n=9)
682 (n=9)
682 (n=9)

One month following surgery 37.5 (n=4)
Over one year following 1438.5
surgery (n= 10)

8-12

42 (91.3)
2 (4.3)
0
12
14 (29.7)
24 (51.1)
16 (84.2)
4 (8.5)

186-364.5
186-773
186-1197
186-1197

354 (n=36)
773 (n=35)
832 (n=33)
825 (n=40)

25-59
390.8-1978

62 (n=21)
1501.5
(n=42)

10.5-12

195.8-450
372-1050
651-1510
449.51556.3
50-102.5
900-2464

.264
.477
.520
.732
1

.189
.132
.086
.190
.057
.353
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Table 3 Continued
Clinical Characteristics and Cancer Treatment in Groups of Patients With and Without
Preoperative Diabetes (N=58) (Median (Mdn) and Interquartile Range [IQR])

With
diabetes
Mdn
n=12 (%)

IQR

Without
diabetes
Mdn
n=46 (%)

IQR

Pa
value

Positive blood culture
C1-last cycle 0
1 (2.2)
.610
Over one year following 0
3 (6.5)
.368
surgery
Type of diabetes therapyb
None reported 5 (41.6)
0
Insulin 3 (25)
0
<.001
Oral therapy c 3 (25)
0
<.001
Insulin and oral therapy 1 (8.3)
0
.048
Number of oral diabetes
.002
medsb
One 1 (8.3)
0
Two 2 (16.7)
0
a
Note. Patients with preoperative diabetes vs. patients without preoperative diabetes by MannWhitney U, chi-squared (χ2), or Fisher’s exact tests; bAt the time of surgery; cDipeptidyl
Peptidase-4 (DPP-4) inhibitors, Sodium-glucose co-transporter-2 (SGLT2) inhibitors,
Sulfonylureas.
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Table 4
Mean Glucose, Standard Deviation (SD), and Coefficient of Variation (CV) Throughout
Chemotherapy in Groups of Patients With and Without Preoperative Diabetes (Median (Mdn)
and Interquartile Range [IQR])
With Diabetes
Mdn
(n=12)
Mean # of Glucose
Measurements (n)
One Month
One Year
Cycle 1- 4
Cycle 1-8
Cycle 1-12
Cycle 1-last cycleb

16.50 (n=12)
72.00 (n=12)
3 (n=10)
9 (n=9)
13 (n=8)
13 (n=12)

Without diabetes
IQR

3.50-35.00
25.00-109.00
3.00-13.50
7.50-62.50
12.00-79.50
12.00-79.50

Mean Glucose mg/dL
One Month
142.75 (n=10) 129.04-185.74
One Year
153.41 (n=12) 131.96-224.55

Mdn
(n=46)

IQR

4 (n=46)
20 (n=46)
3 (n=44)
7 (n=37)
12 (n=23)
11 (n=46)

1-7.5
19.00-29.00
2.00-3.50
6.50-10.50
11.00-17.00
11.00-17.00

Pa
value

.014
.013
.417
.227
.275
.885

115.75 (n=36) 101.76-126.62
107.7 (n=46) 102.37-116.67

<.001
<.001

Cycle 1- 4

175.58 (n=10) 143.74-220.25

107.28 (n=42) 96.46-112.42

<.001

Cycle 1-8
Cycle 1-12

195.25 (n=9)
179.83 (n=8)

129.21-244.79
121.59-244.50

106.7 (n=36) 101.07-121.17
106.38 (n=23) 100.50-128.50

<.001
<.001

Cycle 1- last cycleb

210.75 (n=11) 139.86-248.75

108.78 (n=45) 101.55-115.85

<.001

SD mg/dL
One Month
One Year

28.62 (n=10)
42.69 (n=12)

23.25-51.18
30.55-57.58

17.46 (n=30) 11.87-23.27
18.81 (n=46) 13.28-23.14

<.001
<.001

Cycle 1- 4

36.59 (n=10)

19.63-70.71

9.19 (n=40)

5.54-20.44

<.001

Cycle 1-8

36.47 (n=9)

25.53-93.73

15.17 (n=36) 9.49-19.93

<.001

Cycle 1-12
Cycle 1- last cycleb

38.59 (n=8)
43.20 (n=11)

26.50-96.22
27.14-69-96

15.59 (n=23) 10.69-20.71
16.69 (n=45) 11.13-22.18

<.001
<.001

CV%
One Month
One Year

21.05 (n=10)
26.73 (n=12)

18.59-29.33
18.07-31.84

15.21 (n=30) 10.62-20.34
16.37 (n=46) 12.39-20.37

.011
<.001

Cycle 1- 4

22.30 (n=10)

11.76-33.06

8.69 (n=40)

5.33-17.36

.009

Cycle 1-8

22.76 (n=8)

16.30-39.16

13.36 (n=36) 9.20-17.28

.008

20.70 (n=8)

18.33-41.47

13.36 (n=23) 11.18-17.09

.004

19.57 (n=11)

18.23-30.30

15.12(n=45)

<.001

Cycle 1-12
Cycle 1- last cycle

b

11.53-18.29

Note. Glycemic variability was determined by the SD (mmol/L) and CV. CV was calculated using
the formula of %: (SD÷Mean)x100 (Ceriello et al., 2019; Danne et al., 2017). aPatients with
preoperative diabetes vs. without preoperative diabetes by Mann-Whitney U. bC1-Last cycle
includes all patients who started chemotherapy but may not have completed 12 cycles.
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Table 5
Spearman’s Correlation Coefficients Between Preoperative Diabetes, Preoperative Glucose,
and Pre-chemotherapy Glucose with Mean Glucose, Standard Deviation (SD), and Coefficient
of Variation (CV)
Preoperative
diabetesa
.556**

Preoperative glucose
.575**

Pre-chemotherapy
glucose
.604**

.540**
.400*

.359*
.212

.094
-.088

One year mean
glucose
One year SD
One year CV

.603**

.543**

.414**

.567**
.430**

.326*
.209

.189
.052

Cycle 1-4 mean
glucose
Cycle 1-4 SD
Cycle 1-4 CV

.621**

.550**

.282

.483**
.367**

.122
.003

-.040
-.139

Cycle 1-8 mean
glucose
Cycle 1-8 SD
Cycle 1-8 CV

.582**

.499**

.253

.505**
.394**

.259
.118

.192
.135

Cycle 1-12 mean
glucose
Cycle 1-12 SD
Cycle 1-12 CV

.618**

.597**

.359

.560**
.511**

.339
.292

.273
.168

One month mean
glucose
One month SD
One month CV

Cycle 1- last cycle
.596**
.499**
.225
b
mean glucose
Cycle 1-last cycle SDb .527**
.154
.112
Cycle 1-last cycle CVb .399**
.014
.035
a
b
Note. No diabetes = 0, diabetes = 1 C1-Last cycle includes all patients who started
chemotherapy but may not have completed 12 cycles.
* p<.05 level. ** p<.01 level.
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Table 6
Spearman’s Correlation Coefficients Between Demographic Characteristics and Mean Glucose,
Standard Deviation (SD), and Coefficient of Variation (%CV) in Patients with Diabetes (n=12)
Age

Racea

Genderb

BMI

Marriedc

One month mean glucose
One month SD
One month %CV

.333
.176
.212

-0.494
-.646*
-.646*

0.313
0.244
0.174

.214
.071
-.286

-0.570
-0.570
-0.418

One year mean glucose
One year SD
One year %CV

.224
.007
-.420

-0.307
-0.251
-0.139

0.483
0.338
-0.048

.357
.286
.286

-0.563
-.661*
-0.465

Cycle 1-4 mean glucose
Cycle 1-4 SD
Cycle 1-4 %CV

-.030
-.648*
-.661*

0.087
0.348
0.261

-0.035
-0.035
-0.104

.771
.257
.257

-0.213
0.355
0.355

Cycle 1-8 mean glucose
Cycle 1-8 SD
Cycle 1-8 %CV

-.133
-.150
-.250

0.207
0.000
0.000

0.087
-0.087
-0.260

.800
.900*
.900*

-0.183
-0.183
-0.183

Cycle 1-12 mean glucose
Cycle 1-12 SD
Cycle 1-12 %CV

-.024
-.190
-.333

0.252
0.126
0.000

0.218
0.109
-0.218

.800
.800
1.000**

-0.282
-0.169
-0.282

Cycle 1-Last cycle mean glucose
Cycle 1-Last cycle SD
Cycle 1-Last cycle %CV

.273
.000
-.482

0.075
0.075
0.075

0.231
0.058
-0.346

.714
.714
.771

-0.418
-0.359
-0.120

Note. BMI = body mass index. aCaucasian = 0, non-Caucasian = 1. b Female = 0, male = 1
c
Married = 0, not married = 1.
* p<.05 level. ** p<.01 level
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Table 7
Spearman’s Correlation Coefficients Between Clinical Characteristics and Mean Glucose, Standard Deviation (SD), and Coefficient of
Variation (%CV) in Patients with Diabetes (n=12)
Cancer
Stage

a

Chemo
cycles #

b

XRT

c

Steroid
dose
during
chemo

d

Steroid dose
over one
year

Preoperative
insulin use

Insulin
use at
cycle 8

e

# of DM
meds at
chemo
C1

f

Number
of DM
meds at
last cycle
chemo
-.348
-.609
-.696*
-.259
-.324
-.324
-.058
-.174
-.290
.000
-.137
-.274
.082
.247
.082
.000

One month mean glucose .052
.522
-.564
-.690
.570
.426
-.261
One month SD
.157
.522
-.655
-.762*
.646*
.426
-.348
One month %CV
.216
.522
-.782*
-.810*
.570
.142
-.348
One year mean glucose
.303
.480
-.504
-.479
.307
.358
-.389
One year SD
.275
.218
-.454
-.479
.251
.615*
-.453
One year %CV
.220
-.393
-.151
-.273
-.084
.666*
-.389
Cycle 1-4 mean glucose
-.320
-.193
-.442
.348
.782**
.058
Cycle 1-4 SD
.320
-.025
.164
-.348
.213
-.058
Cycle 1-4 %CV
.320
.059
.224
-.348
.213
-.058
Cycle 1-8 mean glucose
-.137
-.169
-.283
.137
.730*
Cycle 1-8 SD
-.274
.084
-.150
.274
.822**
Cycle 1-8 %CV
-.274
.241
-.050
.274
.822**
Cycle 1-12 mean glucose -.325
-.381
.756*
Cycle 1-12 SD
.000
-.048
.756*
Cycle 1-12 %CV
.313
.262
.756*
Cycle 1- Last cycle mean
-.054
.500
-.277
-.394
.387
.478
-.100
glucose
Cycle 1-Last cycle SD
-.121
.100
-.034
-.212
.194
.657*
-.100
.200
Cycle 1-Last cycle %CV
-.135
-.400
.269
.115
-.129
.657*
.000
.100
a
b
Note. XRT = radiation therapy. DM = diabetes mellitus. Number of adjuvant chemotherapy cycles. Radiation therapy no = 0, yes = 1.
c
Cumulative steroid dose throughout adjuvant chemotherapy. dCumulative steroid dose over one year. eNumber of diabetes
medications taken at start of chemo (C1). fNumber of diabetes medications taken at time of the last cycle of chemotherapy.
* p<.05 level. ** p<.01 level
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Figure 1: Changes in Glycemic Variability Throughout Chemotherapy Treatment
Note. SD=standard deviation, CV = coefficient of variation. *= statistically significant
Changes in glycemic variability over 12 cycles of adjuvant chemotherapy are shown for groups
of patients with (n=8) and without (n=21) preoperative diabetes. The results of the Friedman
Test indicated that there was no statistically significant differences in glycemic variability
across the three time points measured by SD (Cycle 1-4, Cycle 1-8, Cycle 1-12 χ2(2, n=8) = .286,
p=.867) or CV (Cycle 1-4, Cycle 1-8, Cycle 1-12 χ2(2, n=8) = 2, p=.368) in patients with diabetes.
Inspection of the median (Md) values showed an initial decrease in glycemic variability as
measured by SD from Cycle 1-4 (Md= 38.82) to Cycle 1-8 (Md=34.89) and then increased at
Cycle 1-12 (Md=38.59). Similarly, CV initially decreased from Cycle 1-4 (Md=25.67) to Cycle 1-8
(Md=20.77) and then remained stable at Cycle 1-12 (Md=20.70).
In patients without diabetes the Friedman Test indicated there was a statistically significant
difference in glycemic variability across the three time points measured by SD (Cycle 1-4, Cycle
1-8, Cycle 1-12 χ2(2, n=21) = 8.667, p=.013) and CV (Cycle 1-4, Cycle 1-8, Cycle 1-12 χ2(2, n=21)
= 14.10, p=.001). Inspection of the median (Md) values showed an increase in glycemic
variability as measured by SD from Cycle 1-4 (Md= 8.72) to Cycle 1-8 (Md=14.71) and a further
increase at Cycle 1-12 (Md=15.60). Similarly, CV increased from Cycle 1-4 (Md=7.44) to Cycle
1-8 (Md=12.87) and a further increase at Cycle 1-12 (Md=13.36).

136

CHAPTER 5: DISCUSSION

137

CHAPTER 5: DISCUSSION
Summary
The background, integrative review, and study results presented in this dissertation
contribute to the critical gap in research of glycemic variability in patients with stage II-III colon
cancer. The results demonstrated that measuring long-term glycemic variability in patients with
stage II-III colon cancer one year following surgery and throughout adjuvant chemotherapy is
feasible and can serve as a method of assessing glycemic control in patients with and without
Type 2 Diabetes (T2D). The findings show that patients with T2D experienced higher mean
glucoses and glycemic variability one month following surgery, throughout adjuvant
chemotherapy, and within one year following surgery compared to those patients without
diabetes. Significant associations were found between glycemic variability and numerous
demographic and clinical characteristics.
The findings from this study support the Conceptual Model for Glycemic Variability in
Patients with Stage II-III Colon Cancer (Figure 2 in Chapter 1). Preoperative T2D, preoperative
glycemic state, and several demographic and clinical characteristics were associated with
glycemic variability. There were not enough differences in the types of chemotherapy received
or the number of cycles of chemotherapy completed to determine if glycemic variability was
influenced by these clinical characteristics. The study was unable to determine associations
between bloodstream infections and glycemic variability due to the few positive blood cultures
identified in the study sample. The model should be explored in larger studies to further
investigate associations with glycemic variability.
Chapter 1 provided the background for the importance of investigating glycemic
variability in patients with stage II-III colon cancer. The complications associated with higher
glycemic variability in the general population and in those with hematological malignancies raise
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concern that patients with higher glycemic variability and colon cancer, with and without T2D,
may be susceptible to adverse outcomes. The commonly used Hemoglobin A1c (HbA1c) is
known to have reliability issues for reflecting glycemic control in some individuals, this may be
especially true in individuals with cancer treated with surgery and chemotherapy. Evidence from
multiple disciplines is mounting in support of glycemic variability as a method of assessing
glycemic control. Inconsistencies in reporting glycemic variability and the numerous
measurement methods have contributed to challenges in identifying an established cut-point to
determine stable and unstable glycemic control in patients with and without T2D (Kovatchev,
2019).
Chapter 2 presented an integrative review of glycemic variability in patients with
gastrointestinal (GI) cancer. Nearly 1000 articles published between 1/1/1969 and 7/24/2019
were screened to find reports of glycemic variability in patients with GI cancer. No studies were
found that reported glycemic variability as an outcome variable. Only 1.9% of the articles
screened met the inclusion criteria for the review by reporting glucose values or HbA1c with a
measurement of glycemic variability. The review discussed the findings of glycemic variability,
measured as Standard Deviation (SD), Standard Error of Mean (SEM), or Interquartile Range
(IQR), in 1526 patients with GI cancer reported in 19 studies.
The majority of the studies included reports of glucose or HbA1c values and SD following
surgery for gastric or pancreatic cancer. There was a lack of consistency in timing of glucose or
HbA1c measurements and methods of reporting glycemic variability. The review concluded that
patients with T2D experienced higher glycemic variability following GI cancer surgery compared
to those without T2D. Higher glycemic variability was more prevalent in patients with T2D and
pancreatic cancer but, regardless of the site of GI cancer, some patients experienced higher
glycemic variability up to and exceeding one year following surgery. The review identified that
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only one study included patients with colon and rectal cancers (Long et al., 1990) and only two
studies investigated the effect of chemotherapy and radiation on glucose levels (Gemici et al.,
2013; Kandaz et al., 2017). These findings exposed the gap in the literature of glycemic
variability in patients with GI cancer, especially in patients with stage II-III colon cancer who are
treated with surgery and chemotherapy.
The information presented in Chapter 1 and findings discussed in the literature review in
Chapter 2 supported the research presented in Chapter 3 and 4. Glycemic variability values
within one year following surgery in patients with stage II-III colon cancer, with and without T2D,
treated with surgery +/- chemotherapy are reported in Chapter 3. Findings from investigating
glycemic variability within one month following surgery, throughout adjuvant chemotherapy,
and within one year following surgery in patients with stage II-III colon cancer, with and without
T2D, treated with chemotherapy, are shared in Chapter 4.
The purpose of this dissertation study was to examine glycemic variability within one
year among adult patients treated with surgery with or without (+/-) chemotherapy for stage IIIII colon cancer. The Specific Aims were:
1. Among patients with stage II-III colon cancer (n=165), +/- Type 2 Diabetes (T2D),
treated with surgery +/- chemotherapy, describe associations between glycemic
variability and patient demographic (i.e., gender, age, body mass index, race,
socioeconomic, employment, insurance, marital status) and clinical characteristics
(i.e., stage of cancer, date of colon cancer surgery, prescription T2D therapy,
cumulative steroid dose, neutrophil-to-lymphocyte ratio) within the first month and
within one year following surgery.
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2. Describe glycemic variability using all clinical glucose measurements in patients with
stage II-III colon cancer (n=165), +/- T2D, +/- chemotherapy, within the first month
and within one year following surgery.
3. Determine glycemic variability within the first month and within one year following
surgery among patients with stage II-III colon cancer (n=165), +/- T2D, treated with
surgery +/- chemotherapy.
4. Determine glycemic variability within the first month following surgery to glycemic
variability between cycle 1 and cycles 4, 8, and 12 of chemotherapy in patients with
stage II-III colon cancer, +/- T2D, who received surgery +/- chemotherapy (n=58).
5. Analyze associations between T2D status, preoperative glycemic state, and prechemotherapy glycemic state with glycemic variability between cycle 1 and cycles 4,
8, and 12 of chemotherapy and within one year following surgery in patients with
stage II-III colon cancer treated with surgery + chemotherapy (n=58 ).
The study included an Exploratory Aim to examine associations between glycemic
variability, the type of chemotherapy prescribed, the type of chemotherapy
administered, the number of chemotherapy cycles completed, and the occurrence of
bloodstream infections within the first month following surgery, during chemotherapy
treatment, and within one year following surgery in patients with stage II and III colon
cancer (n=165; n=58) +/- T2D.
Chapter 3 provides the findings of Aims 1 - 3 and the Exploratory Aim in patients treated
with surgery for stage II-III colon cancer (n=165). For Aim 1, numerous associations between
glycemic variability with demographic and clinical characteristics were noted. There were
differences between results of glycemic variability by T2D status prior to surgery and by method
of measurement, SD or CV. Published studies have also reported inconsistent associations
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between glycemic variability with demographic characteristics and method of measurement, SD
or CV (Akirov et al., 2019; Figueira et al., 2019; Gude et al., 2017).
The strongest associations were observed between Caucasian race and lower
cumulative steroid dose over one year, with higher glycemic variability by SD, one month
following surgery in patients with T2D. There were very few non-Caucasian patients in the
sample and the results of the associations between race and glycemic variability should be
interpreted with caution, especially considering the limited and inconsistent published reports
of associations between glycemic variability and race (Echouffo-Tcheugui et al., 2019; Hill et al.,
2011; Kim et al., 2014). To the PI’s knowledge, this dissertation study is the first report of
associations between glycemic variability and steroid dose. The inverse association between
lower cumulative steroid dose over one year and glycemic variability one month following
surgery in patients with T2D may be explained by clinical decisions to limit the use of steroids in
patients with T2D, particularly those with unstable glycemic control.
Studies have reported inverse associations between body mass index (BMI) and
glycemic variability in patients with (Wang et al., 2017) and without T2D (Gude et al., 2017). The
findings of this study revealed a moderate association between lower BMI in patients with T2D
and higher glycemic variability, by SD and CV, one month following surgery. Insulin is prescribed
to patients with uncontrolled T2D; therefore, it was not surprising that insulin use at the time of
surgery and at one year following surgery was moderately associated with higher glycemic
variability by SD. Moderate associations also were observed between higher preoperative
glucose, male gender, being married, and higher glycemic variability by SD, within one year
following surgery.
In patients without T2D, fewer and weaker associations were observed between
demographic/clinical characteristics and glycemic variability. A weak association was identified
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one month following surgery between having federal/government insurance and older age and
glycemic variability by SD. In addition, federal insurance status, chemotherapy, a higher number
of prescribed antibiotics over a year, and development of metastatic disease within one year
were found to be weakly associated with glycemic variability, by SD, within one year following
surgery. The weak association between receiving chemotherapy and lower one year SD was
initially surprising. However, the association may be explained by the favorable clinical
characteristics that are taken into consideration when deciding cancer treatment. Perhaps the
patients with higher glycemic variability in the study had unfavorable clinical characteristics that
classified them as poor candidates for chemotherapy. Higher glycemic variability is known to be
associated with patients with longer hospital stays and higher risk of mortality (Akirov et al.,
2017; Hammer et al., 2009; Mendez et al., 2013).
While investigating the EHR for chemotherapy details, six patients without T2D that
were diagnosed with metastatic colon cancer within one year following surgery were identified.
As glycemic variability has been associated with cancer development in the general population
(Kobayashi et al., 2020; Saito et al., 2019), associations between progression of metastasis
within one year following surgery and glycemic variability within one month and within one year
following surgery were investigated. A weak association was observed between progression of
cancer into metastatic disease within one year following surgery and higher CV one month
following surgery in the group of patients without T2D. These results should be interpreted with
caution as a limited number of patients in this study developed metastasis within a year. Future
studies of the association of cancer progression and glycemic variability are warranted.
For Aim 2, glycemic variability in patients with T2D, measured by SD within one month
and within one year following surgery, was greater than 29 mg/dL. This value was previously
reported as the level at which there is an increased risk of adverse events in patients following
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allogeneic hematopoietic cell transplant for hematologic cancers (Hammer et al., 2009). Patients
without T2D did not experience a SD of greater than 29 mg/dL within one month or within one
year following surgery. Glycemic variability measured by CV within one month and within one
year following surgery did not exceed 36% in patients with or without T2D. A CV of 36% reflects
the value that separates stable and unstable glycemic control in patients with T2D using
continuous glucose monitoring systems (CGMS) (Monnier et al., 2017). The findings support the
need for further investigation of glycemic variability in patients with colon cancer. There are no
established values of SD or CV that define high or low glycemic variability in patients specifically
with colon cancer and T2D. Furthermore, there are no established high cut-point values for SD
or CV in patients without T2D.
For Aim 3, patients with T2D were found to have higher glycemic variability within one
month and within one year following surgery for stage II-III colon cancer compared to those
without T2D. The findings were consistent with reports from prior published research (Gude et
al., 2017; Suh & Kim, 2015; Xia et al., 2017) and the published integrative review included in
Chapter 2.
The study included an Exploratory Aim to examine associations between the types of
chemotherapy prescribed/administered, number of chemotherapy cycles completed, and
occurrence of bloodstream infections. There were not enough differences in the types of
chemotherapy prescribed and numbers of chemotherapy cycles completed to identify
significant associations between types of chemotherapy and number of cycles completed with
glycemic variability. No significant associations were identified between positive blood cultures
over a year following surgery and glycemic variability, but very few patients had positive blood
cultures. Interestingly, the number of antibiotics prescribed within one month and within one
year following surgery (a clinical characteristic of interest in this study) was weakly associated
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with higher SD within one month and within one year following surgery; the reason for
prescribed antibiotic use (e.g., prophylactic or treatment of infection) is not known.
Chapter 4 describes the results of Aims 1, 4, 5, and the Exploratory Aim in patients with
stage II-III colon cancer treated with surgery followed by adjuvant chemotherapy (n=58). For
Aim 1, numerous associations between demographic and clinical characteristics and glycemic
variability were identified in patients with T2D treated with chemotherapy. Associations differed
based on the timing of the glycemic variability assessment. The strongest associations between
glycemic variability throughout chemotherapy were younger age and higher BMI. When
evaluating glycemic variability within one month and within one year following surgery,
Caucasian race and being married demonstrated the strongest associations with glycemic
variability.
Associations were identified between younger age and higher BMI with higher glycemic
variability throughout chemotherapy. Findings reported in Chapter 3, in the larger sample of
patients evaluated within one year following surgery and reports from associations with
glycemic variability in the general population without T2D showed the opposite to be true (Gude
et al., 2017; Wang et al., 2017). There is no clear reason for why younger patients or those with
higher BMI who receive chemotherapy experience higher glycemic variability during
chemotherapy. Possible reasons may include clinical characteristics such as risk factors for colon
cancer including higher BMI, genetic alterations, and lifestyle factors that may contribute to
diagnosis of cancer at a younger age. Younger patients with colon cancer are often found to
have more aggressive tumors and advanced stage of disease (Weinberg & Marshall, 2019).
Younger patients with cancer are being heavily investigated in 2020. The associations of
Caucasian race and being married with experiencing higher glycemic variability one year
following surgery in patients with T2D was consistent with the findings reported in Chapter 3.
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Specifically, Caucasian race was strongly associated with higher glycemic variability one month
following surgery and being married was strongly associated with higher glycemic variability
within one year following surgery. The results should be further validated in larger studies due
to the small number of non-Caucasian patients and unmarried patients included in this study.
The only demographic characteristic associated with glycemic variability in patients
without T2D was not being married; a moderate association was observed between higher
glycemic variability by SD between cycle 1 – last cycle of chemotherapy and with SD and CV one
year following surgery. The opposite was found in patients with T2D; the reasons for the
differences in associations between patients with and without T2D regarding marital status and
glycemic variability in patients with stage II-III colon cancer is unclear. There were no significant
associations noted between clinical characteristics and glycemic variability in patients without
T2D.
Similar to the findings reported in Chapter 3, preoperative insulin use and insulin use at
cycle 8 of chemotherapy were associated with higher glycemic variability. Specifically, patients
who were taking insulin prior to surgery experienced higher glycemic variability, by SD, one
month following surgery. Insulin use at cycle 8 was associated with higher glycemic variability,
by SD and CV, between cycle 1-8, cycle 1-12, cycle 1-last cycle, and within one year. These
findings were expected as insulin is often used to treat patients with uncontrolled T2D. Those
patients who were taking fewer oral T2D medications at completion of their chemotherapy had
higher glycemic variability one month following surgery. With a larger sample size of patients
with T2D, we may have identified a more consistent association with the number of T2D
medications and glycemic variability at various time points. Similar to the associations reported
in Chapter 3, a lower cumulative steroid dose throughout chemotherapy treatment and at one
year following surgery was associated with higher glycemic variability, by SD and CV, one month
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following surgery. Clinical decisions to prescribe lower doses of steroids in patients receiving
chemotherapy for stage II-III colon cancer were likely influenced by concerns of glucose control.
For Aim 4, glycemic variability one month following surgery and throughout
chemotherapy was higher in patients with T2D than with those without T2D. This was similar to
the findings reported in Chapter 3 and consistent with findings from the literature (Gude et al.,
2017; Mandolfo et al., 2019; Suh & Kim, 2015; Xia et al., 2017). In patients with T2D, the
glycemic variability throughout chemotherapy was higher than the glycemic variability reported
within one month following surgery. A significant increase in glycemic variability was observed
throughout treatment of 12 cycles of chemotherapy in patients without T2D; however, this was
not seen in patients with T2D. Future studies are needed as these are the first known reports of
glycemic variability experienced throughout adjuvant chemotherapy in patient with stage II-III
colon cancer.
For Aim 5, having a preoperative diagnosis of T2D was strongly associated with higher
mean glucoses and with higher glycemic variability, by SD and CV, within one month following
surgery, at each time point throughout adjuvant chemotherapy, and within one year following
surgery. Higher preoperative glucose value was moderately associated with higher glycemic
variability within one month and within one year following surgery, by SD. Interestingly, higher
blood glucose value prior to chemotherapy was not associated with higher glycemic variability
throughout adjuvant chemotherapy. These findings support that hyperglycemia and glycemic
variability represent two unique, important factors when assessing glycemic control. A high
glucose value before surgery or prior to the initiation of chemotherapy did not infer a patient
will experience higher glycemic variability throughout adjuvant chemotherapy.
The PI attempted to investigate the Exploratory Aim in the sample of patients who
received chemotherapy. There were too few differences in type of chemotherapy
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prescribed/administered, number of chemotherapy cycles completed, too few positive blood
cultures, and too few antibiotic prescriptions to evaluate associations with glycemic variability
within one year and throughout adjuvant chemotherapy.
Strengths and Limitations
Use of the EHR allowed the opportunity to measure glycemic variability throughout
adjuvant chemotherapy and over a year following surgery. The ability to evaluate 6,509 glucose
values from 165 patients, including 2,311 glucose values in 58 patients treated with
chemotherapy, over a year following surgery for stage II-III colon cancer was a strength. The
retrieval of automatically imputed laboratory values from the EHR mitigated the risk of error. An
attempt to find missing glucose values and confirm T2D status was conducted thorough a
rigorous search in the EHR. The search entailed reviewing scanned laboratory reports,
chemotherapy administration records, medical and nursing notes, and anesthesia records.
Despite the efforts to retrieve missing data, it is possible that there were some patients who had
prediabetes or T2D who were not recorded as such. Additionally, the past medical and
medication history in the EHR are largely reliant on patient reports which raises accuracy
concerns. There may have been patients who elected to receive chemotherapy or seek care
from another institution following surgery, the data from those patients is considered missing
and not captured.
The study was limited by the use of a small sample of unmatched groups from a single
institution. The decision was made a priori to include all the patients that met the inclusion
criteria to inform future research. The glucose values retrieved from the EHR were assumed to
be random assessments, the timing of meals in relation to the assessment was not known.
Differences were observed between patients with and without T2D in the number of glucose
values assessed throughout chemotherapy and over the year following surgery. Additionally, not
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all patients received 12 cycles of chemotherapy. These limitations resulted in a dataset of
variables that were not normally distributed which further limited the statistical analyses to
nonparametric tests and no multiple regression analyses could be performed. Recognizing the
limits of performing a retrospective study using data from the EHR, the PI believes the benefit of
the knowledge gained outweighs the limitations.
Implications
This dissertation study has several implications for research. The results provide the first
assessment of glycemic variability throughout adjuvant chemotherapy and within one year
following surgery in patients with stage II-III colon cancer. Future research needs to expand on
this primary investigation of glycemic variability in colon cancer and investigate glycemic
variability in a larger number of patients with colon cancer and other cancer types (e.g., breast,
lung, prostate, pancreatic, gastric, etc.). Studies of matched groups, including a uniform number
of glucose measurements, to investigate associations between demographic characteristics and
glycemic variability are needed; especially regarding gender, race, and BMI as there are
inconsistencies in the literature (Echouffo-Tcheugui et al., 2019; Hill et al., 2011; Kim et al.,
2014). The duration of T2D prior to the diagnosis of cancer and the impact that comorbidities
may have on glycemic variability in patients with cancer should be explored. The impact that
glycemic variability has on outcomes such as infection and length of hospital stay following
surgery for colon cancer surgery warrants investigation. Larger studies of patients with cancer
who are treated with chemotherapy should investigate associations between treatment
toxicities, symptoms, and glycemic variability. Associations should be explored between type of
surgery (e.g., laparoscopic, robotic, or open surgery), systemic cancer treatment (e.g.,
chemotherapy, targeted therapy, and immunotherapy), and glycemic variability. The
commercial availability of CGMS devices offers clinicians and researchers the opportunity to
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perform robust, prospective research to assess glycemic control in patients with cancer. This
study supports the use of glycemic variability, by SD or CV, as a practical method to assess
glycemic control in future studies. Studies should investigate associations between diabetes selfmanagement and glycemic variability, particularly in older patients and in those taking insulin.
Research of patients in survivorship care should include studies of associations between cancer
recurrence rates, overall survival, and long-term glycemic variability. The use of predictive
models will be critical in identifying key risk factors for higher glycemic variability and cancerrelated symptoms/outcomes.
This study has limited implications for practice at this time as glycemic variability is an
emerging measurement of glycemic control. Questions remain on how to best incorporate
measurement of glycemic variability into the management of patients with T2D. Further
questions remain of the utility of glycemic variability in patients without T2D. Based on the
results from this study clinicians must be mindful that fluctuations in glucose can occur in
patients with stage II-III colon cancer, with and without T2D. Patients taking insulin may be most
vulnerable to higher glycemic variability throughout chemotherapy. Clinicians need to
incorporate the topic of glycemic control into the pre-chemotherapy teaching for patients with
colon cancer and T2D.
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